

Transcriptional control in cancer

Ilaria Cherchi

Telegram: @ilariacherchi

Elisa Pettinà

Telegram: @elispettina

Github: <https://github.com/ilariache/Transcriptional-control-in-cancer>

December 5, 2022

Contents

1	Transcription	3
1.1	Recap on transcription	3
1.2	2- Transcriptional Control in Cancer	3
1.2.1	Transcription initiation	3
1.2.2	Chromatin remodeling	5
1.2.3	Nucleosome organization	6
1.3	3 (1)	7
1.3.1	Main nucleosome modifications in promoters:	8
1.4	4 - TCiC (1)	12
1.4.1	Structural basis of the nucleosome transition during RNA pol II passage - Kujirai et al 2018	12
1.5	Termination	16
2	Enhancer regulation	20
2.1	5 - TCiC (1)	20
2.1.1	Wnt signalling pathway	22
2.2	6- Transcriptional Control in Cancer	26
2.3	CREP/p300	26
2.3.1	TSSa-RNAs transcription	28
3	CTCF	32
3.1	7- Transcriptional Control in Cancer	32

CONTENTS

4 TCIC	46
4.1 13- Transcriptional Control in Cancer	46
4.2 Targeting transcription in cancer	46
4.2.1 Target transcription in cancer	51
4.3 15- Transcriptional Control in Cancer	52
4.4 BRD4	52
4.5 YAP/TAZ	53
4.6 TEAD	55
4.6.1 YAP/TAZ/TEAD	55
4.7 17- Transcriptional Control in Cancer	56
4.8 Nuclear receptors	56
4.8.1 Estrogen receptor α	57
4.8.2 ER α) in breast cancer	57
5 Genome instability	62
5.1 19- Transcriptional Control in Cancer	62
5.2 Transcription and genome instability	62
5.2.1 R-loops	62
5.2.2 HOTTIP-dependent R-loop formation regulates CTCF boundary activity and TAD integrity in leukemia	65
5.2.3 HOTTIP lncRNA Promotes Hematopoietic Stem Cells Self-Renewal Leading to AML-like Disease in Mice	67
5.3 20- Transcriptional Control in Cancer	67
5.4 Transcription and genome instability II	67
5.4.1 DNA damage	67
5.4.2 Apical kinases	68
5.4.3 Topoisomerase	71

Chapter 1

Transcription

1.1 Recap on transcription

1.2 2- Transcriptional Control in Cancer

RNA polymerases are *highly processive enzymes*, able to continuously extend transcripts without releasing them, yet unable to resume transcription if they are detached from the nascent RNA.

RNA pol II is responsible for the transcription of all protein-coding genes, plus snoRNA genes, miRNA genes, siRNA genes, lncRNA genes and most snRNA genes. RNA pol II enzyme is composed by 12 subunits.

1.2.1 Transcription initiation

The **core promoter** is a short sequence encompassing ~ 50 bp upstream and ~ 50 bp downstream of the TSS consisting of core promoter elements.

We start from the unbound promoter and **TFIID complex**, formed by TAFs (14-15 subunits) and TBP. **TBP** is responsible for the recognition of the TATA box, TAF1-2 for Inr region and TAF6-9 for MTE and DPE.




Figure 1.1: Screenshot 2022-09-16 at 12.11.22.png

1.2. 2- TRANSCRIPTIONAL CONTROL IN CANCER




Figure 1.2: Screenshot 2022-09-16 at 15.53.19.png

Once TFIIA and TFIIB reach TFIID, the upstream promoter complex forms. In particular, the promoter region becomes bent. Lastly, Pol II and TFIIF are recruited at the promoter region to initiate transcription.

Once ATP is released, promoter clearance is activated allowing the PIC complex to reach the open conformation and to start transcription. **TFIIP** induces torsional stress by rotating it with respect to a fixed site (TBP bound), melting DNA leading to the open complex state (OC). TFIIP promotes unwinding of approximately 10 bp of promoter DNA. When ***Pol II locates the TSS, it transits into a processive elongation mode. Dissociation of general transcription factors enables the formation of the Pol II elongation complex (addition of elongation factors).

Summarising, transcription initiation follows:

1. TFIID + TBP promoter recognition → PIC assembly
2. TFIIA recruitment stabilises the TBP-DNA complex
3. TFIIB stabilises TBP-DNA and TBP-DNA-Pol II complexes, binds the template strand to position DNA for initiation of RNA synthesis (setting the TSS); stimulates RNA synthesis by allosterically rearranging active site residues and stabilizing closed polymerase clamp
4. TFIIF heterodimer associates with polII and prevents non-specific interaction of polII with DNA; stabilizes the PIC by interacting also with TFIIB; influences TSS selection; stimulates phosphodiester bonds formation
5. TFIIE binds pol II (clamp) and facilitates the recruitment of TFIIP to the initiation complex; providing a bridge between polII and TFIIP; binds single stranded DNA; TFIIE stabilizes the open promoter; facilitates ATPase/kinase activities of TFIIP
6. TFIIP opens promoter DNA, phosphorylates RNA pol II CTD; promotes translocation of ssDNA into polII cleft
7. Factors binding modify the structural conformation of the preassembled complex TFIID-TBP-promoter structure becomes visible to TFIIB and A, the hole structure is visible to RNAPol II-TFIIF which is a complex and so on...

1.2. 2- TRANSCRIPTIONAL CONTROL IN CANCER

8. Pol II is positioned at the core promoter by the combination of TFIID, TFIIA and TFIIB through protein-protein interactions and protein-DNA interactions
9. TFIID then melts 10-15 bp of DNA in order to position the single strand template in the polII cleft (open complex) to initiate RNA synthesis
10. The CTD of PolII will be phosphorylated by the TFIID kinase subunit during the first 30 bp of transcription when PolII loses its contacts with GTFs before proceeding onto the elongation stage

How does this start? *What makes a promoter all of a sudden accessible to TBP and so to TFIID?* DNA sequence is always there, what makes it visible/accessible to the general transcription factors ?

1.2.2 Chromatin remodeling

Nucleosomes are the functional units of protein. In nucleosomes the position of each major groove facing the histone octamer is designed as **superhelix location** (SHL), numbered from 0 at the Dyad to ± 7 .

Proteins cannot easily associate with DNA sequences that touch the nucleosomal histone surface. Nucleosomal DNA is bent around the histone octamer – target sequences can be distorted or unrecognizable. GC-rich sequences with AA, TT or TA dinucleotides spaces by 10 bp bend more easily and display higher affinity for the histone octamer “nucleosome positioning sequences”.

Nucleosome unwrapping is influenced by histone PTMs. In particular, certain combinations of PTMs display synergistic effects. For instance, covalent modifications of histone proteins can significantly alter the organization and function of chromatin. Examples:

- acetylated H3K56 enhances the unwrapping of the DNA at the entry/exit sites of the nucleosome.
- acetylated H4K91 leads to nucleosome instability - H4K91 lays in the H3-H4 and H2A-H2B interaction surface

Histone modifications may also recruit proteins and enzyme to regulate the chromatin state. Remember that nucleosomal fibers can fold into higher order structures that may be even less accessible.

With the use of energy nucleosomes can be remodelled:

- Histone octamers can slide along DNA
- Can be fully or partially disassembled
- Histones can be replaced with histone variants and post-translationally modified

These processes are carried out by the synergic activity of **chromatin remodeling complexes** and **histone chaperones**.

1.2.2.1 Techniques to study chromatin remodelling

- **MNase:** micrococcal nuclease is able to digest linker DNA, therefore to isolate nucleosomes. We have no information about the sequence, but we can assess the bp length of isolated DNA.
****Cons: some mapped entities are not nucleosomal, preference for cutting A/T rich regions.
- **ChIP-seq:** after DNA sonication, immunoprecipitation and immunocomplex purification are performed (with protein-specific antibodies). DNA and proteins are cross-linked and purified, then bound DNA is analyzed by massively parallel short-read sequencing. ChIP-seq is relatively simple (technically), but does not have a high resolution due to non-uniform DNA fragmentation. Resolution also depends on library/sequencing setting.

1.2. 2- TRANSCRIPTIONAL CONTROL IN CANCER




Figure 1.3: Screenshot 2022-09-16 at 16.26.04.png

1.2.3 Nucleosome organization

Nucleosome organization can be described as a combination of nucleosome occupancy and positioning:

- Occupancy: average number of nucleosomes measured within a specific genomic region within a cell population
- Positioning: probability of a nucleosome reference point being at a specific genomic coordinate (same dyad)

Most nucleosomes in animal genomes are poorly positioned, but there are regions with **phased arrays** of well positioned nucleosomes.

Most promoters contain a nucleosome free region (NFR) and a defined nucleosomal architecture that aids the recruitment of Pol II. A subset of genes may have a nucleosome in their promoter region, which is depleted during gene activation. DNA sequences containing relatively high GC content tend to wrap nucleosomes with higher affinity in vitro.

ATP-dependent chromatin remodelers act at promoter regions. **Remodels the structure of chromatin (RSC)** is a chromatin remodelling factor acting on core promoters. It retains a cavity which can accommodate nucleosomes.

1.2.3.1 Nucleosome remodelling

The unpeeling of DNA segments from the histone surface can lead to a delocalization of nucleosomes (their sliding), removal or replacement of histones or to the complete eviction of the nucleosome, also dependent on associated histone chaperones.

ATP-dependent chromatin remodelling enzymes can act cooperatively with **histone chaperones** to generate or disassemble nucleosomes. Chaperones associate with histones upon their synthesis, escort them into the nucleus, and aid in their specific association with DNA during different processes such as DNA replication, repair, or transcription. Histone Chaperones participate in assembly or disassembly nucleosomes in vitro or in vivo without using the energy of ATP.

Example: SWR and Inositol-requiring protein 80 (INO80) chromatin remodelling complexes regulate histone turnover and histone variant H2A.Z deposition. HIRA complex regulates H3.3 deposition at genes and regulatory elements.

H2A.Z has extended acidic patches on the surface which stimulate remodeling activities and weaken DNA interaction and may play a role in Pol II recruitment - it is lost at promoters upon RNA PolII

1.3. 3 (1)




Figure 1.4: Screenshot 2022-09-16 at 16.30.29.png




Figure 1.5: Screenshot 2022-09-23 at 15.22.44.png

loading. H2A.Z comprises 15% of total H2A and it is post translationally modified (acetylated, polyubiquitinilate...).

The most rapid **nucleosome turnover** occurs over promoters, tRNA, and small nucleolar RNA genes (often studied in over expression settings).

1.3 3 (1)

PIC formation at a core promoter requires a nucleosome depleted region. This could be achieved by **RSC** binding to the AT-rich region in the promoter, freeing the NDR. Next, **HIRA** performs the replacement of H3-H4 by H3.3-H4 and **SWR** replaces the H2A-H2B dimer by H2A.Z-H2B dimer. Finally, **INO80** replaces H2A.Z-H2B by H2A-H2B. The resulting scenario exhibits unmethylated CpG islands in NDR region, allowing for PIC formation.

1.3. 3 (1)




Figure 1.6: Screenshot 2022-09-22 at 21.36.39.png

Chromatin Immunoprecipitation (ChIP) experiments to determine protein-DNA interactions require a *crosslinking* step.

1. Crosslinking: formaldehyde and a quencher are required to covalently modify DNA
 1. Lysis
 2. Antibody binding
 3. Immunoprecipitation
 4. Wash steps
 5. Crosslink reversal
 6. DNA purification and quantitative PCR
 7. DNA and protein analysis

1.3.1 Main nucleosome modifications in promoters:

Most promoters (98%) occupied by Pol II are also occupied by histone H3K4me3 and acetylated H3K9 and H3K14 (Gunter et al., 2007).

- **H3K4me3**-modified nucleosomes ****are found at sites of transcription. H3K4me3 enrichment is detectable in almost 80% of all protein-coding genes within 1 kb of known or predicted transcript start sites. Only 30-40% of protein coding genes are expressed in human embryonic stem cells. Histone H3K4me3 is observed also at the promoters of genes for which there is no evidence of transcription in ES cells - typically lower than in active genes. Genes not enriched in H3K4me3 are found in clusters along the genome; The vicinity of these genes on the genome suggest that their expression they may be regulated sinergically.
- **H3K9-14Ac** were enriched at the promoters of nearly 70% of genes, including both transcriptionally active and inactive genes. Nearly all of the promoters (>95%) acetylated on H3K9 and H3K14 were also enriched for H3K4me3.
- **H3K36me3** and **H3K79me2** modifications occur almost exclusively downstream of promoters that produce detectable transcripts in ES cells

1.3.1.1 RT-qPCR based detection of 5' RNA transcripts of inactive genes

1. Assay components and DNA template: forward primer + probe + reverse primer

1.3. 3 (1)




Figure 1.7: Screenshot 2022-09-22 at 21.49.05.png

2. Denatured template and annealing assay components:
3. Polymerization and signal generation

Genes that do not produce full length mRNAs can experience transcription initiation. The majority of all genes contain H3K4me3-modified nucleosomes in both ES and differentiated cells. Differential H3K4 methylation is found in 25% of genes. These genes have cell type-specific expression pattern and cell type-specific function.

Summary: Results suggest that most protein-coding genes in human cells, including most genes thought to be transcriptionally inactive, experience the hallmarks of transcription initiation. H3K4me3 and H3K9-14Ac modifications, together with RNA Pol II, occupy the promoters of approximately 79% of protein-coding genes in ES and differentiated cells, but only about half of these produce detectable transcripts. The co-occupancy of Pol II with H3K4me3- and H3K9,14Ac-modified nucleosomes at genes without detectable levels of transcription suggests that a large fraction of human genes experience transcription initiation without transcript completion.

Protein-coding genes can fall into three groups of regulatory behaviour:

- *Productive*: the actively transcribed genes are occupied by nucleosomes with histone modifications that are hallmarks of both initiation (H3K4me3 and H3K9-14Ac) and elongation (H3K36me3 and H3K79me2)
- *Non-productive*: experiences transcription initiation without evidence of transcript elongation or accumulation.
- *No initiation*: genes that are excluded from experiencing transcription initiation, where mechanisms that prevent transcription initiation must predominate.

1.3.1.2 Global run-on sequencing (GRO-seq)

Global run-on sequencing (GRO-Seq) enables to map the presence of elongating RNA pol in the chromatin context by detection of the nascent transcripts. The *Sarkosyl* treatment permeabilizes

1.3. 3 (1)




Figure 1.8: Screenshot 2022-09-22 at 21.58.03.png




Figure 1.9: Differential phosphorylation of RNA Pol II CTD during transcription.

nuclear membranes, prevents RNA Pol from binding DNA (if not already bound), disassembles chromatin and dissociates pausing factors.

Results: only few paused genes are transcriptionally inactive. **Pausing** can be seen as a mechanism for tuning expression from active genes rather than a means of gene inactivation. The paused Pol II remains stably associated with the nascent RNA and is fully capable of resuming elongation; however, further signals are needed to elicit the transition to a productive elongation complex.

Pausing index: Ratio of Pol II density on promoter to gene body.

The **CTD** undergoes dynamic changes in phosphorylation and dephosphorylation during transcription. The CTD is a long unstructured domain consisting of $Y_1S_2P_3T_4S_5P_6S_7$ tandem repeats. **Cyclin-dependent kinases** (CDKs) are serine/threonine specific kinases; cell cycle-associated CDKs regulate cell cycle progression. Transcription-associated CDKs are key regulators of gene expression. PTMs of the PolII CTD coordinate transcription and RNA processing

Differential phosphorylation of RNA Pol II CTD during transcription.

1.3. 3 (1)




Figure 1.10: Screenshot 2022-09-22 at 22.14.15.png

1.3.1.3 Transcription pausing mechanism

NELF is recruited on PolII by **DSIF** which contributes to pausing by forming 2 nucleic acid clamps. CDK9 with cyclin T, referred to as **P-TEFb** complex, enables pause-release leading to transcription elongation.

Pol II distribution profiles surrounding all promoters reveal a general decrease in promoter occupancy upon NELF depletion. Knockdown of NELF and consequent reduced Pol II pausing decreases gene expression, because nucleosomes occupy the promoter regions and thus block the expression of these genes by preventing TF and GTF binding.

Promoter-proximal pausing represents an additional layer of regulation to accommodate increased demands for precise and rapid gene regulation during organism development and responses to stress. It might be beneficial to maintain highly regulated promoters poised in an open chromatin state, to prevent their incorporation into the more inaccessible, condensed heterochromatin that exists in metazoans. Housekeeping genes lack pronounced pol II pausing.

Main hypotheses for the function of pol II pausing:

- establishing permissive chromatin: paused Pol II helps to maintain the nucleosome-deprived structure by blocking nucleosome assembly over promoter sequences. Pausing would thus keep the promoter region accessible for activator and transcription factor binding.
- rapid or synchronous activation: at a gene with paused Pol II, gene activation could proceed simply through recruitment of positive transcription elongation factor b (P-TEFb), thereby triggering the rapid release of paused Pol II into productive elongation without the need of the PIC assembly.
- integration of signals: pausing represents a separate step in the transcription cycle for factors to act and allows for combinatorial control between transcription factors that recruit the transcription machinery (TF1) and those that trigger pause release (TF2), where both would be necessary for gene activation.
- checkpoint in early elongation: on the left, arrows depict interactions between the capping enzyme complex (CEC) and DSIF–NELF as well as the Ser5 phosphorylation of the carboxy-terminal heptapeptide repeat domain (CTD) of Pol II, which is thought to stimulate capping activity. The hat represents the 5 RNA cap. In the centre, P-TEFb-dependent phosphorylation events release paused Pol II and create a platform for binding of RNA-processing factors (RPFs) on the Ser2-phosphorylated CTD of Pol II, as shown on the right.

7SK snRNP represses transcription by sequestering and inhibiting P-TEFb. Super elongation com-

1.4. 4 - TCIC (1)

plex (**SEC**) and Bromodomain containing protein 4 (**BRD4**) complexes represent active forms of P-TEFb that can promote the release of Pol II from pausing.

BRD4 competes for binding to P-TEFb with the P-TEFb inhibitory complex HEXIM- 7SK, and it is recruited to TSSs by multiple means, including histone acetylation. The SEC can interact with a subset of co-activators such as Mediator, polymerase- associated factor 1 (PAF1) and Integrator, the latter of which is a complex that interacts with the CTD of Pol II. The SEC and BRD4 predominantly mediate the recruitment P-TEFb, but their regulatory importance and composition with regard to paused Pol II release seems to vary across different genes, cell types and stimuli. Ser2 phosphorylated CTD promotes the recruitment of other transcription elongation factors, including SPT6.

A large repertoire of transcription activators crucially involved in cancer, including MYC and NF-kB, target P-TEFb, DSIF or NELF to gene promoters.

1.4 4 - TCiC (1)

From previous lectures: multi-step mechanism of recruitment of pol II. Enzymatic activity is necessary to activate pol II through phosphorylation. DSIF and NELF pausing allows to stop and efficiently activate transcription.

During the elongation phase, RNA pol II faces nucleosomes. In order to proceed with elongation, RNA pol II needs to overcome the issue: *histone turnover* is predominantly observed at transcription start sites.

1.4.1 Structural basis of the nucleosome transition during RNA pol II passage - Kujirai et al 2018

The aim of the research paper was to reconstitute RNA pol II and a nucleosome separately in vitro and analyze their interaction. The DNA stretch is required to be around 153 bp to achieve histone wrapping for obtaining a nucleosome. Keep in mind that is not easy to recapitulate the PIC formation in vitro. The first step involves unwinding and exposing DNA. For bypassing this step, it is possible to use an already “melted” initiation site ready for transcription. Once RNA pol II and **TFIIS** elongation factor are added, transcription can start.

1.4.1.1 Nucleosome structure

A single base pair is centred on the nucleosome *dyad*, which defines the pseudo 2-fold symmetry axis of the nucleosome. The major groups in the DNA stretch facing the dyad are *superhelical location* (SHL) -7 and -1. In nucleosomes, SHLs are formed at regular intervals (10bp) from the dyad interacting with histone K and R residues.

Kujirai and Kurumizaka, *Curr Op. Struct. Biol.*, 2020

1.4.1.2 Cryo-EM

Cryo-Electron Microscopy is technique applied for molecule structure determination, which allows to reconstruct structures almost at the atomic level. We freeze samples in vitro (-80° C, -90° C) with

1.4. 4 - TCIC (1)




Figure 1.11: Kujirai and Kurumizaka, *Curr Op. Struct. Biol.*, 2020



Figure 1.12: Screenshot 2022-10-05 at 22.57.06.png

liquid ethane. The sample is hit with a photon beam instead of light from different orientations, obtaining a pool of 2D images. Finally, a 3D image is reconstructed through an algorithm, providing a resolution in Armstrongs.

Most of the times, RNA Pol II was associated with the nucleosome at position SHL(-5) or SHL(-1), as well as SHL(-6) and SHL(-2). Other sites were quickly encountered and passed by Pol II, whereas the aforementioned ones required a bit more time. Looking at the electrophoresis results without the addition of TFIIS, RNA pol II can only reach SHL(-5), while when we add it also SHL(-1) is observed.

RNA Pol II elongates RNA up to SHL(-5) in the absence of the elongation factor and until reaching SHL(-1) in the presence of TFIIS. Pausing at SHL (-5) and (-1) represent rate limiting steps of nucleosomal transcription in vitro.

Kujirai et al., *Science*, 2018

SHL(-6) is at the entry site, DNA has not been “peeled” yet from the nucleosome. At these sites H3 and H4 interact with DNA, we can appreciate the presence of modifications.




Figure 1.13: Kujirai et al., *Science*, 2018

1.4. 4 - TCIC (1)




Figure 1.14: Screenshot 2022-10-05 at 23.02.04.png




Figure 1.15: Kujirai and Kurumizaka., *Curr Op. Struct. Biol.*, 2020 Template looping results in histone transfer from ahead of the transcribing RNAPol II to behind

The dimer H2A and H2B is completely exposed after the “peeling” of the first DNA turn. This results in the uncovering of a positively charged region, which can be easily accessed by other compounds and rewrapped by “foreign DNA” i.e. not the DNA which was there previously.

1.4.1.3 Summary of the main results

- Nucleosomes can inhibit initiation and elongation of transcription.
- Nucleosome free regions are present within core promoters.
- Transcription pausing occurs at the first well-positioned nucleosome (+1).
- RNA polII transiently pauses when it transcribes nucleosomal DNA.
- Elongation factors are required for productive transcription.
- The transcription efficiency is modulated by histone post-translational modifications, histone variants and histone exchange which may affect histone-DNA contacts in the nucleosome re-leaving the major RNAPII pausing sites.

1.4.1.4 Template looping

DNA upstream of Pol II starts wrapping around the upstream nucleosome, pushing pol II to continue. This process does not require disassembly.

Kujirai and Kurumizaka., *Curr Op. Struct. Biol.*, 2020 Template looping results in histone transfer from ahead of the transcribing RNAPol II to behind

1.4. 4 - TCIC (1)




Figure 1.16: Lai and Pugh, *Nature Review Mol Cell Biol.* 2017




Figure 1.17: Van Oss *et al.*, *TRENDS Biochem Sci.* 2017

It is not only required to have TFIIS, other factors are involved: Spt4/5 and Paf1C (elongation factors), **FACT** and **Spt6** (histone chaperones) with acidic patches balancing the positively charged histones exposed in unwrapping.

FACT(facilitate chromatin transcription) interacts with the H2A-H2B dimer and we observe the formation of the *hexasome* (only 8 subunits) in the process of histone turnover. FACT activity is also influenced by H2A-H2B dimers ubiquitylation. Nap1 (HC) stabilizes hexasomes favouring transcription elongation.

Lai and Pugh, *Nature Review Mol Cell Biol.* 2017

In a similar fashion, H3.3 is bound by HIRA, TF for “recycling”, regulated by acetylation.

Paf1C elongation factor interacts directly with Pol II, in particular with s5 phosphorylation. It also interacts with DSIF and FACT. When pol II is elongating, it promotes the phosphorylation of NELF and DSIF. Ctr9 is a subunit of Paf.

Van Oss *et al.*, *TRENDS Biochem Sci.* 2017

1.4.1.5 Structural basis of nucleosome disassembly and reassembly by RNA P II elongation complex with FACT - Ehara *et al.*

Recent article: once H2A-H2B are partially exposed, FACT starts interacting with the nucleosome. When the full exposure of the nucleosome is reached, FACT promotes a transit from downstream to upstream, assisting the template looping procedure.

Chromatin remodeling factors also participate in transcription elongation:

- **RSC:** arrangement of NDR between +1 and -1 nucleosomes
- **CHD1** and **ISWI:** arrangement of nucleosome spacing and separation of closely packed nucleosomes

1.5. TERMINATION




Figure 1.18: Screenshot 2022-10-10 at 10.35.12.png




Figure 1.19: Porrua & Libri, Nature Review Mol Cell Biol, 2015

- **Fun30:** facilitation of nucleosome disassembly

1.5 Termination

Transcription termination occurs when the elongation complex is disassembled, and both RNA Pol II and the RNA are released. In our cells a signal on DNA is required, a *polyA site* followed by U rich/G rich regions. Once polyA is transcribed, we observe the SPSF complex recruitment, which recognizes the AAA site and proceeds to RNA cleavage and polyadenylation. Meanwhile, RNA pol II will continue transcription (slowly, probably due to allosteric changes in pol II structure bound to the complex) of mRNA which will be degraded due to the exposed 5' end. **Torpedo model:** XRN2 degrades this RNA and leads to the dissociation of pol II from DNA.

Porrua & Libri, Nature Review Mol Cell Biol, 2015

1.5.0.1 Promoter reporter assay

Since transcription at core promoters can be induced by distal elements, we can perform a promoter reporter assay to investigate which regions actively regulate transcription.

In order to perform the assay, we need to clone the upstream region of a known gene e.g. GFB. **Cloning vector:** enhancer + CNV (promoter and enhancer) + multiple cloning sites (**MCS**) + GFB (coding sequence + polyA site) + OriC + amp.

1. Linearize a plasmid by cutting it with restriction enzyme (HIND) and run it on the gel for extraction

1.5. TERMINATION




Figure 1.20: Anderson & Sandelin, *Nature Review Gen.* 2019

2. Ligation
3. Transformation through heat shock
4. Integration screening (check amp resistance)

After cloning, we transfet the compound in cells. GFB will be barely detectable. We could start again with a longer sequence and clone it in from of GFB, but it would still be undetectable. It is required to employ a longer gene for observing signal. By playing with deletions, we understand that we only need small regions: 100 bp at TSS and a proximal enhancer region.

Anderson & Sandelin, *Nature Review Gen.* 2019

The enhancer can be hundreds of kilobases away from the promoter, could be upstream or downstream, even in introns. In order to check if a gene is an enhancer we need to place it around a reporter gene with different combinations.

- *Core promoter*: sequence that enables to initiate transcription (immediate vicinity of a TSS) by docking the pre-initiation complex (PIC)
- *Promoter*: refers to a sequence which can autonomously drive high levels of productive transcription (proximal enhancer + core promoters)
- *Enhancer*: distal element. The enhancer can be transcribed, but the mRNA is not stable and not codifying for protein.

1.5.0.2 Promoter types

Not all promoters have a TATA box, we have 3 different kinds of promoters:

1. **Type I ('adult')**: TATA box and sharp TSS. No CpG, nucleosomes are not well positioned → minority of promoters. Tissue-specific expression.
2. **Type II ('ubiquitous')**: no TATA box and CpG islands. Broad TSS, ordered nucleosome configuration.
3. **Type III ('developmentally regulated')**: featured by polycomb regulation, large CpG islands extending into the body of gene.

Lenhard *et al.*, *Nature Rev Cancer* 2012

1.5. TERMINATION




Figure 1.21: Lenhard *et al.*, *Nature Rev Cancer* 2012

1.5.0.3 Transcription factor binding

Most of the times, TFs require co-factors and direct binding; sometimes the *effector domain* can be either a ligand-binding domain or PPI domain.

TFs cooperate and synergize to gain access to their binding sites. For instance, factor A can bind alone to the unwinded first part, then B binds. In general we can observe:

- passive cooperativity
- TF-TF interactions
- enhanceosome model

Most TF binding occurs in clusters (<1kb) on nucleosome depleted regions. Regulatory networks are usually created with the same TF regulating different genes depending on other TF and cofactors availability.

Pioneer TFs are able to access their own binding sites independently of nucleosome/chromatin binding. For instance, **FoxA** HTH domain is really similar to H1 linker histone. HTH binds DNA minor groove: it has a trans activator domain and it is able to bind core histone. Once pioneer TF bind, they are able to pull DNA from the nucleosome creating a more accessible stretch. Examples:

- SOX2 exposes DNA for OCT4 → *sequential binding mechanism* for recruiting multiple TFs, rather than simultaneous
- FoxA1 enables Estrogen Receptor alpha recruitment

Other mechanisms we can observe are the recruitment of acetylases e.g. p300 to enhance nucleosome destabilization.

Transcription is dynamically regulated but not constantly occurring. The core promoter will accommodate a number of pol II, which will then transcribe (burst). Different core promoters can have a different burst size. Enhancers do not change this size (which is given by promoter structure), but increase the number of bursts per time.

Haberle & Stark, *NatRevMolCelBiol*. 2018

1.5. TERMINATION




Figure 1.22: Haberle & Stark, *NatRevMolCelBiol.* 2018

Chapter 2

Enhancer regulation

2.1 5 - TCiC (1)

Enhancer regulation is controlled by specific transcription factors with a DBD. Most of the times, TFs interact with PIC through co-factors. In particular, the Mediator is a key co-activator complex of RNA pol II transcription regulation.

2.1.0.1 Mediator complex

The Mediator complex is a multi subunit complex, composed of almost 30 subunits. CDK8 is the only module with enzymatic activity.

The Mediator complex can interact with hundreds of TFs and integrate their function, allowing cooperation and regulation of multiple sites in enhancer regions. Examples: SOX,c-Myc,...

Since the Mediator is a multi-subunit structure, a conformational change in one subunit propagates to the whole complex.




Figure 2.1: Screenshot 2022-10-07 at 10.47.50.png

2.1. 5 - TCIC (1)




Figure 2.2: Screenshot 2022-10-07 at 10.50.30.png




Figure 2.3: Soutourina, *Nature Review Mol Cell Biol.* 2018

The interaction with Pol II prevents the catalytic interaction: the core mediator has mutually exclusive interactions.

The Mediator functions as a bridge between the TFs bound to the enhancers and the PIC at core promoters; DNA looping involves *cohesins* (circle DNA). The interaction with enhancers occurs first and is more stable than the core promoter one.

Soutourina, *Nature Review Mol Cell Biol.* 2018

The Mediator stimulates transcription at several levels: assembly of the PIC, chromatin organization, transcription elongation, nucleosome displacement at TATA-box promoters. After Pol II promoter escapes, the Mediator interacts with Cdk8 to activate pause release. The Mediator presence at TATA regions inversely correlates with nucleosome occupancy : indeed, it is able to bind acetylated histones and interact with chromatin remodelling complexes contributing in histone eviction.

The Mediator has been defined as GTF (general TF), however it preferentially associates with enhancers and its occupancy at core promoters is generally low and transient.

Once the Mediator is interacting with the PIC, CDK8 is displaced; afterwards, the Mediator is able to recruit it again to activate Cdk9, allowing the pausing mechanism.

2.1. 5 - TCIC (1)




Figure 2.4: Allen and Taatjes, *Nature Reviews Mol Cell Biol.* 2015




Figure 2.5: Bugter *et al.*, *Nature Review Cancer*, 2021

Allen and Taatjes, *Nature Reviews Mol Cell Biol.* 2015

The multi-subunit and modular structure of the Mediator enables to respond to multiple signalling cascades activating transcription. Different subunits can be engaged in PPIs; we are interested in many of them, in particular oncogenes usually interact with the mediator.

2.1.1 Wnt signalling pathway

Wnt signalling pathway is a relevant pathway for morphogenesis and embryonic development, as well as adult tissue homeostasis. Its activation is associated with cell proliferation and cell renewal.

The pathway occurs at a plasma membrane, where ~20 ligands interact among themselves and with a core receptor (either LRP5 or LRP6). A

- Off: XIN1 forms a *destruction complex* with APC, CK1, GSK, which recruits β -catenin, a relevant co-activator. The activation is performed through phosphorylation or ser and threonine residues, which will then recruit btrCP ubiquitinylase and lead to b-cat degradation.
- On: when Wnt is present, the complex is sequestered and therefore β -catenin is not phosphorylated and ubiquitinylated, it remains present in the cell. Among target genes, AXIN2 promotes the recruitment and formation of destruction complex, others are plasma membrane proteins which promote *endosome mediated degradation* of WNT.

Bugter *et al.*, *Nature Review Cancer*, 2021

Wnt is synthesized in the endoplasmic reticulum, lipid modified and released from cells through EVs (or can remain attached to membrane of secreting neighbouring cells). It can spread and reach different sites.

Excessive β -catenin activity in cancer can occur due to:

2.1. 5 - TCIC (1)




Figure 2.6: Screenshot 2022-10-10 at 11.04.14.png

- inactivating mutations in members of the destruction complex
- negative feedback pathway (RNF43 or ZNRF3) and activating mutations β -catenin

Genetic alterations in the WNT pathway occur in most cancer types with some components of the pathway showing tissue specificity. All WNT mutations converge in enhancing β -catenin activity, although with different extent, and cooperate with other driver mutations to promote tumorigenesis. Mutation are considered early (APC) or late (RNF43) events and associate with different tumor subtypes. APC mutant tumor leads to many clinical features: depending on the function and position in the pathway of the gene, the downstream effect can be very different.

In absence of β -catenin (Wnt pathway off), TLE and HDAC bind TCF and stop transcription. β -catenin subcellular translocation is presumed to function thanks to the binding of adaptor proteins. β -catenin needs to interact with different TFs, among which TCF family members are the most common and expressed in different forms. They all recognize the same binding site. In particular, different isoforms of TCF7 and LEF1 are highly expressed in colorectal cancer.

2.1.1.1 β -catenin structure

β -catenin structure acts as a binding platform for numerous interactions. It is composed of 781 aa residues in humans and divided in:

- central highly repetitive sequence with *Armadillo sequence* important for nuclear activity.
- Helix-C conserved structure close to CTD
- C-terminal transcription activator domain (CTTA)

Key interactors: E-cadherin and A-catenin → structural function, focal adhesion. Decrease in E-cadherin is found in EMT. E-cadherin cad is stabilized by β -catenin, therefore with low levels of β -catenin we observe an E-cadherin decrease in EMT.

2.1. 5 - TCIC (1)




Figure 2.7: Valenta *et al.*, EMBO J. 2012

The function of β -catenin, both structural and signaling, is regulated by post-translational modifications.

RNA pol II is also loaded on inactive genes; to foster elongation we require β -catenin, which can recruit PAF1 complex. The majority interact with the CTTA domain, which serves as a binding platform or trans-activation domain.

Valenta *et al.*, EMBO J. 2012

McDonald *et al.*, Dev Cell, 2009

2.1.1.2 The canonical Wnt/ β -catenin pathway is crucially involved in colorectal cancer

The **APC gene** was first identified by being mutated in a hereditary colon cancer syndrome termed familiar adenomatous polyposis. Most cases of sporadic colorectal cancer result from loss of both APC alleles. Loss of APC function leads to the inappropriate stabilization of β -catenin and the formation of constitutive complexes between β -catenin and the intestinal TCF family member TCF7l2/TCF4. Patients with hereditary Axin2 mutations display a predisposition to colon cancer. Aberrant activation of the canonical Wnt/ β -catenin pathway occurs in almost all colorectal cancers, contributing to their growth, invasion and survival.

Luciferase reporter genes: firefly and renilla Luc, of the two only one has a responsive site to TCF. It is a control for the efficiency of transfection.

Let's see which genes are involved in the regulation of β -catenin through RNAi in DLD1 cells: 34 genes are necessary for β -catenin activity and 166 candidate genes are necessary for HCT116 cells proliferation. By merging the two groups, we can identify a set of 9 potential regulators of

2.1. 5 - TCIC (1)




Figure 2.8: McDonald *et al.*, *Dev Cell*, 2009




Figure 2.9: Firestein *et al.*, *Nature* 2008

colon cancer proliferation and β -catenin activity: CDK8, CSK1G3, CSNK1E, DKK1, MAP3K14, MLLT7, PLK4, TAOK1 and ZAK.

Genome wide analysis of chromosome copy number alterations (CNA) in human CRC biopsies revealed amplification of chr. 13 region including CDK8. Immunohistochemical analysis of CDK8 expression in the same 50 specimens revealed elevated protein levels in 26% colon cancer samples, including those that showed CDK8 CN gain [the brownish colour in IHC indicates that CDK8 expression increases].

Firestein *et al.*, *Nature* 2008

These observations indicate that CDK8 is amplified and overexpressed in a substantial fraction of colon cancers. In particular, CDK8 action is not a passenger effect, it is a *driving proliferation*. There is a huge difference from *in vitro* and *in vivo* tumor setting: in order to obtain more suitable experiments, we can look at the transforming potential (as not all proliferating cells are necessarily tumor cells). If we combine β -catenin in catalytically dead CDK8 we drop the effect, but it is not completely abolished - as β -catenin can bypass the need engaging interactions with others.

Main conclusions of the article

2.2. 6- TRANSCRIPTIONAL CONTROL IN CANCER

- CDK8 acts as an oncogene in a substantial fraction of colorectal cancers
- CDK8 kinase activity is essential to regulate β -catenin dependent transcription and transformation
- CDK8 acts in part by co-activating β -catenin driven transcription in colon cancer with high CDK8 expression and β -catenin activity

Therapeutic interventions that target CDK8 kinase activity may be of clinical value in colorectal cancer

Almost all Mediator subunits have been found to be mutated/deregulated in a huge list of cancers e.g. MED12 subunit in prostate cancer.

2.2 6- Transcriptional Control in Cancer

TCiC

2.3 CREP/p300

CREB-binding protein (CBP) and p300 is a heavily regulated TF. Differently from the Mediator, it is a monomer and has several trans-activation domain, which enable it to interact with TF and PIC. It has histone acetyltransferase activity (HAT) or lysine acetyltransferase activity (KAT). Chromatin will be modified by increasing accessibility and also TF regulation.

2.3.0.1 CREP/p300 structure

- 4 transactivation domains
- histidine rich or glutamine rich regions.
- Zinc fingers domain for PPIs
- bromodomain and PHD interact with histones
- lysine acetyltransferase domain (HAT)

Wang *et al.*, *Cell Mol Life Sci.* 2013

There are no intrinsically disordered regions, they fold after interacting with ID proteins.

Note that among CBP/p300 binding partners we find both oncosuppressor genes and oncogenes, as well as co-factors.

TF interactions are mediated by TADs. There is a combined interaction among multiple TFs and CBP, enabling the integration of the function of several TFs. The interaction with enhancers does not necessarily correlate with transcription activation; only when the appropriate number and identity is recruited on the enhancer, it becomes functional.

CBP/p300 levels in cells are limiting and different genomic sites or pathways compete for their activity.

2.3. CREP/P300




Figure 2.10: Wang et al., *Cell Mol Life Sci.* 2013




Figure 2.11: Screenshot 2022-10-12 at 09.01.27.png

In the case of p300, we observe the *co-binding mechanism* with common cofactors or common complexes (transcriptional synergy).

Co-activators facilitate transcription by numerous mechanisms:

- Adaptors function: bridging TFs to the PIC, recruitment of polII to core promoters, recruitment of chromatin remodelling and modifying enzymes to core promoters
- Scaffolding function: facilitating protein-protein and protein-DNA interactions, promoting/stabilizing PIC formation
- Enzymatic activities: Kinase (mediator), KAT (CBP/p300) targeting histones, TFs and non-TF proteins (acetylation of P-TEFb enhances its activity).

Their activity can vary from gene to gene depending on TF involved and regulated by PTMs and chromatin accessibility.

In particular, CBP/p300 can regulate pro-proliferative pathways, e.g., cell cycle regulation.

Indeed, CBP and p300 gene are frequently mutated in cancer - mutually exclusive. Most are missense mutations (single nucleotide), some deletions and insertions. Mutation hotspots are found at the catalytic domain (KAT). We always need to consider the context of genetic instability characterizing cancer: depending on which signal is activated/repressed, a particular mutated form can either exert proliferative or oncosuppressor activity [often loss of heterozygosity].

2.3. CREP/P300

The many functions of CBP/p300 can be differentially exploited in cancer depending on the context, leading the CBP/p300 proteins to act as oncosuppressors or oncogenes. Depending on cellular identity, dysregulated pathways and transcription rewiring, cancer cells may select for the CBP/p300 alterations most advantageous for survival and growth.

2.3.1 TSSa-RNAs transcription

Transcription by RNA Pol II is often thought to occur unidirectionally, however we also observe an enrichment of transcripts in the opposite direction with respect to forward transcription. TSSa-RNAs (TSS antisense) surround promoters in nonrandom and divergent orientations. Sense TSSa-RNAs map downstream of the associated promoter, overlapping genic transcripts and peaking in abundance between +0 and +50 nt downstream of the TSS. Antisense TSSa-RNAs peak between nucleotides -100 and -300 and can range from 20 to 90 nt (detected by Northern blot). The mere fact of having high abundance of TF can recruit pol II, which can act *spuriously*: it not only transcribes following the functional direction, but also in the opposite direction (with different pre-initiation complexes).

It is presumed that these small transcripts are abortive transcription tentative; stalling can occur if RNA is not properly processed e.g. no recruitment of cap proteins, so after degradation and when RNA pol II is displaced, a short sequence (which was protected by pol II) remains at the site. In general, there is a bias towards the directionality of these transcripts, confirming the previous hypothesis; highly expressed genes all have TSSa-RNA.

Although divergent transcription initiation is widespread and might have functions, productive elongation by RNAP II occurs primarily unidirectionally, downstream of TSSs. Promoter upstream transcripts (PROMPTs) are longer than TSS-a and are more stable, while PASRs overlap on the TSS.

Different families of noncoding RNAs are transcribed at promoters of protein coding genes:

- Transcription start-site-associated (**TSSa**) RNAs are short transcripts (18-24 up to 90bp), do not overlap TSS, sense or antisense of the mRNA
- Promoter associated short transcripts (**PASRs**): capped bidirectional short RNA (20- 100nt long) that overlap TSS
- Promoter upstream transcripts (**PROMPTs**): capped bidirectional ncRNAs, map upstream of active promoters (-500 and -2000 from TSS)

Potential functions

- Help modulating chromatin structure due to the Pol II activity and/or binding with chromatin i.e. help sustaining nucleosome free regions
- Noncoding RNAs as precursors for short ncRNA (especially longer ones)

[RNase are degraded by the exosome, which is a multi-subunit complex which recognizes uncut RNase.]

ENCODE (Encyclopedia of DNA Elements) has the objective to map all RNAs, which are divided into long and short and by cellular location - either cytoplasmatic or nuclear.

2.3. CREP/P300

- 74.7% of human genome is transcribed (primary transcripts)
- short RNAs detected: ~160,000 transcripts (~40,000 exonic, ~55,000 intronic, ~45,000 intergenic, ~23,000 gene-intergene boundaries)
- long RNA transcripts detected: ~60,000 transcripts from ~19,000 protein coding genes (GENCODE v7); 73,325 transcripts mapping within intergenic regions (also enhancers) and antisense elements (long noncoding RNAs and possible new genes)

TSS identified within enhancer regions with transcription proceeding for several kilobases giving rise to **eRNAs**.

How can we distinguish enhancers? By analysing epigenetic marks, TF binding and especially co-factor binding (ChIP-Seq).

Poly(A)- mostly enriched, but also Poly(A), detectable by CAGE hence capped. Transcribed enhancers on average show a significantly different pattern of chromatin modification than non-transcribed ones e.g. H3K27ac, ... All the markers are associated with transcription initiations.

In addition to the fact that enhancers need to regulate transcription to allow RNA production, transcription can occur bidirectionally and the enhancer itself can be transcribed.

- **poised enhancer:** TF bound to the enhancer LDTF (lineage-determinant TF), which is a pioneer TF. We can see some histone modifications for activation, but they are not sufficient to fully activate the promoter. Even pol II can or cannot be recruited, it is not yet acting on a target promoter, but it is active.
- **active enhancer:** Mediator recruitment, HAT activity, nucleosome remodelling complexes and transcription occurs on the enhancer.

Example: the signalling of NFKB TF starts in cytoplasm, it only is shuttled to nucleosome upon a specific signal. Since it is not pioneer TF, it can only bind to poised enhancer → cell-line dependent mechanism.

An active enhancer shows high levels for H3K4me (especially me3), Pol II and Ser5P, H3K27ac, while other elongation markers are less observed. Example of cell-specific regulation: TAL1 TF, oncogene expressed in endothelial cells and erythroid cells, we witness enrichment of H3k4me2 at enhancer sites. Active enhancers associate with chromatin looping.

2.3.1.1 Properties of eRNAs

- eRNAs are transcribed from putative enhancer regions characterized by high levels of H3K27ac and the lack of the repressive H3K27me3 mark
- These genomic regions are bound by TFs and associate with transcriptional co-regulators including Mediator, histone acetyltransferase CBP/p300
- eRNA-expressing enhancers are also enriched with PIC
- eRNAs are 50-2000 nt in length and generally exhibit shorter half-lives compared to mRNAs and lncRNAs. They are generally not spliced or polyadenylated
- Enhancer transcripts are preferentially enriched at enhancers engaged in chromatin looping with promoters of protein-coding genes and other enhancers, which is a feature correlated with enhancer activity

2.3. CREP/P300




Figure 2.12: Studniarek *et al.*, *Trends in Genetics*, 2021

eRNAs proposed functions:

Studniarek *et al.*, *Trends in Genetics*, 2021

Last function: Intrinsically disordered proteins → phase separation mechanism. We are enriching the density of enzymes in a particular region.

In particular, eRNA can promoter chromatin remodelling recruitment to reach appropriate configurations for chromatin at TSS.

2.3.1.2 Assessing whether the CRC 8q24 risk region acts as an enhancer

Most mutations in cancer are SNPs and mainly occur outside of coding regions. Driver mutations are commonly found at coding regions, but also outside of it. One way in which we can analyze non-coding region is assessing the frequency of mutation for a region. In 2007, two different studies found that some SNPs located in 8q24 were highly associated with colorectal cancer.

In particular, the rs6983267 SNP G allele (over T allele) on 8q24 associates with increased risk of colorectal cancer. Homozygosity for the risk G allele in cancer increases CRC risk 1.5 folds.

One way to study non-coding SNP is to understand whether it can be a regulatory region:

1. ChIP-Seq: the risk locus with G shows an enrichment in RNAP II, methylation and p300
2. Reporter assay: 1.5 kb long region including the risk allele can function as an enhancer. The G risk allele shows increase reporter activity than the WT allele for the risk allele. It is not a 10 fold difference, suggesting it is not a driver mutation.

Epigenetic and reporter assay data indicate that the CRC risk allele functions as an enhancer. The rs6983267 SNP is located with a **TCF** consensus binding site (A/T)(A/T)CAA(A/T)GG. This site is not an exact consensus sequence, but if we have a G on the last position we achieve a higher affinity. By performing ChIP on TCF4, the peak for G allele is higher than T. There is no gene for hundreds of kbs, but if we move forward we find Myc. Since TCF4 is an effector of Wnt pathway and Myc is a beta-catenin target, the SNP can be placed in Myc enhancer region. Instead, no association between MYC mRNA expression and CRC risk allele was identified in either normal colon or tumor

2.3. CREP/P300

samples. However, 3C experiments show a physical interaction between the risk allele and MYC promoter was detected in CRC lines but not fibroblasts.

Conclusions:

- The CRC risk locus shows enhancer-like functions in CRC cell lines
- The CRC risk allele interacts with TCF4
- This locus physically interacts with the MYC promoter

Hypothesis: the rs6983267 risk allele may regulate MYC during tumorigenesis

Another article from 2009:

Computational approach predicts that the rs6983267 would impact TCF4 binding site, since a change from T to G is predicted to considerably increase the affinity for TCF4 binding. They use a different approach to verify whether TCF4 is interacting with the risk region.

EMSA: in vitro incubation of recombinant proteins (oligonucleotide of interest with radioactive mark). Run electrophoresis: TCF4 with its own sequence, unrelated sequence and SNP alleles sequence. TCF4 can bind the risk allele G, much less affinity for T allele.

Activation of the WNT pathway through GSK3B inhibition indicates WNT responsive enhancer activity. Reporter assay to obtain a biological readout of the process: the entire site is required for the interaction and should not be further mutated. The risk G allele shows 1.5 fold increase in WNT responsitivity compared to the T allele.

Chapter 3

CTCF

3.1 7- Transcriptional Control in Cancer

Lecture 8 - TCiC

RNA stability is tightly regulated, we expected that uncut RNAs are less stable than processed ones. The export in the cytoplasm of mRNAs is mediated by Transcription Exports (TERT); non-spliced/retained RNAs in the nucleus can be targeted for degradation. This is a side concept, but still linked inextricably to transcription and cell proliferation. By increasing transcription export also gene expression increases, and therefore cells are able to achieve a higher proliferation.

From last lecture: the presence of eRNAs gives us the chance to discriminate between active and poised enhancers. How can we study the impact of enhancers in cancer?

- chromatin marks
- reporter assay

Hypothesis: the rs6983267 risk allele may regulate MYC during tumorigenesis

TCF4 and β -catenin were enriched with the rs6983267 risk allele.

The peak is placed right on rs6983267 risk allele in ChIP-seq (e). In Sanger seq. (f), we cannot discriminate if a G or T is present in the input, whereas in the pull down of TCF4 G has a clearly higher signal.




Figure 3.1: Screenshot 2022-10-14 at 10.52.51.png

3.1. 7- TRANSCRIPTIONAL CONTROL IN CANCER




Figure 3.2: Screenshot 2022-10-14 at 10.54.02.png

By analyzing TCF4 binding sites genome-wide, the risk allele was found to be the fourth most enriched site.

In order to assess whether MYC was indeed regulated by Wnt signalling pathway, the authors of the paper cloned a sequence including the risk allele upstream of a lacZ gene. The expression recapitulated an endogenous MYC (checked by *in situ* hybridisation).

Conclusions:

- A high risk allele SNP for CRC was identified resulting in a TF binding site within an enhancer
- The risk allele is more sensitive to TCF4 binding and WNT activation
- The risk allele regulates MYC expression (most likely) upon WNT signalling activation
- The presence of this allele may render cells hypersensitive to the WNT pathway resulting in deregulated (increases) expression of MYC with consequent pro-proliferative behaviour

Recently, it was observed that the conservation of the locus including the risk allele is particularly high in mammals (28 species). By looking at the Northern blot for the conserved sequence, there was a transcript of about 0.5 kb length which was called CCAT2, expressed in different cancer cell lines. Looking at RT-qPCR analysis from tumor biopsies vs normal: tumor expressed higher levels with respect to control. Interestingly, increased expression was observed for microsatellite regions, while the expression in antisense was almost undetectable. This suggests that the enhancer is transcribed unidirectionally, giving rise to CCAT2 transcript, which does not codify for proteins → long non-coding RNA.

CCAT2 expression is significantly higher in microsatellite stable (MSS) colon cancer tumours, compared to non-neoplastic mucosal samples and MSI-H tumours. *In situ* hybridization confirms increased expression of CCAT2 in tumor cells.

Retroviral-mediated expression of CCAT2 promotes tumor growth in HCT116 (MSI-H) cells. In particular, the endogenous is 1000 higher than HCT116 - control to check for overexpression.

When looking at the extent of proliferation, a lack of effect on 2D cell growth by CCAT2 was observed. **Xenograft study** (transduce with retroviral vector clones and inject in mice): CCAT2 increased subcutaneous tumor formation in a mouse xenograft model.

Modulation of the CCAT2 levels can affect the metastatic capacity of cells. In particular, a higher CCAT2 expression was detected in primary CRC tumors from patients with metastasis and higher CCAT2 RNA levels associate with shorter metastasis-free survival in breast cancer patients.

Is this related to MYC/enhancer interaction or only to CCAT2? The tumours showing increased MYC expression also had an increased CCAT2 expression. By depleting CCAT2 through siRNA, a decrease is also produced in MYC expression.

3.1. 7- TRANSCRIPTIONAL CONTROL IN CANCER

Gene known-down approaches:

- *small interfering RNAs*: tiny oligo RNA, transfected in cells, bp with target RNA and enable degradation
- *s h RNAs*: always short RNA bp with target, but expressed like microRNA in a plasmid. Pro: stabilized (cannot stabilize oligo), Cons: highjack DICER and other RNA enzymes
- *antisense oligonucleotide*: completely different chemistry, instead of phosphodiesteric bond between different bases, can have sulphur atoms making them resistant to endonucleases.

MYC is a downstream target of Wnt. Pull down for TCF a long non-coding RNA is bound to it (not in vitro). Instead of CHIP, extract RNA followed by PCR.

Conclusions:

1. An ~335-kb DNA loop brings the rs6983267 genomic region close to the MYC locus, and this physical association may contribute to the enhancer function of the SNP-containing region on MYC transcription.
2. The enhancer region is transcribed into a long noncoding RNA (CCAT2), and the SNP status affects CCAT2 expression.
3. The CCAT2 transcript up-regulates WNT activity and increases expression levels of WNT target genes (including MYC). This regulation by CCAT2, possibly through its physical interaction with TCF7L2, may lead to genomic instability and promote cell growth.
4. CCAT2 expression is regulated by transcriptional factors TCF7L2, indicating a positive feedback loop between CCAT2 and WNT signaling.

It is not the end of it! CCAT2 can interact with BOP1, regulating AURKB (Aurora B Kinase) and leading to unbalanced segregation of chromosomes during mitosis → chromosome instability. CCAT2 is also found in serum (can evade from cell through exosome), can be used as therapeutic target and diagnostic tool.

The enhancer can work at very high distance with respect to the gene of interest; this means that an enhancer has the possibility to regulate many promoters, how can its activity be directed to a specific target promoter?

Insulator sequences prevent the propagation of enhancers signals along the chromatin fiber through their enhancer blocking function mediated by proteins. Insulator genes are usually found at a region densely distributed with genes. They can act in long distance, do not need specific direction and the sequences are recognized by proteins. The main insulator binding protein is a factor called CCCTC-binding factor (CTCF).

CTCF has a peculiar DBD with 11 zinc fingers; each of them can recognize a short consensus motif. In principle, it could recognize huge regions and be very flexible in recognition capabilities, as combinatorial use of its 11 ZF allows binding to 50bp target sites with high sequence variations. CTCF regulates transcription both positively and negatively and can operate as a transcription factor. At first, it was recognized as a repressive TF: it has the ability to shape the DNA molecules, not merely binding on a site distorting it, and to recruit co-factors.

3.1. 7- TRANSCRIPTIONAL CONTROL IN CANCER




Figure 3.3: Screenshot 2022-10-14 at 11.20.37.png

CTCF is the main *insulator-binding protein* in vertebrates. ChIP shows that CTCF binds thousands of sites in the human genome. We can find it mainly in intergenic regions and introns, as well as promoter regions. There is an extensive overlap of CTCF binding sites among cell lines (12000). The consensus sequence recognized by CTCF is the same among cell lines.

CTCF is enriched at the H3K27me3 domain boundaries (CTCF barrier sites). A larger genomic region was analyzed in different cell lines. Almost no overlap was found in the CTCF barrier sites between CD4T cells and HeLa cells, suggesting that CTCF barriers are cell-type-specific. In some cells the site is at the boundary, in others not.

We now know that heterochromatic marks spread up to insulator sequences, which can be recognized by protein and recruit directly or indirectly chromatin remodelling factors.

Main findings:

- CTCF can bind to the same locus in different cell types
- CTCF binding can separate active and repressed chromatin, functioning as barrier to heterochromatin spreading
- CTCF exerts its barrier ability in a cell type dependent manner

The function of CTCF appears to be regulated at least at two levels:

1. binding of CTCF to the target sites.
2. binding of interacting proteins, providing its functionality

3.1. 7- TRANSCRIPTIONAL CONTROL IN CANCER




Figure 3.4: Screenshot 2022-10-14 at 19.51.43.png

3.1.0.1 Cohesin mediates transcriptional insulation by CCCTC-binding factor

CTCF was found to interact with cohesins (composed of SMC3, SMC1, SCC1 and SCC3 subunits), which are essential to maintain sister chromatids connected from S phase to metaphase. Cohesins are loaded on chromosomes during G1, but the function is exerted later on. For achieving anaphase, the ring is cut by securins - regulated by APC.

Cohesin is expressed in differentiated postmitotic cells. We expect that replicating cells express cohesin, as it is heavily required in cell cycle. Pulling down SMC3 in mouse brain we still observe a signal, it is probably linked to an additional function of the complex. During G2 we expect that cohesins are holding together sister chromatids, which instead are absent in G1; the binding site is the same, checked by ChIP-Seq → cohesin binds to the same sites independent on cohesion CTCF and cohesion share several binding sites.

By looking at CTCF KO the binding is lost, as well as SCC1 binding.

Cohesin and CTCF co-occupy thousands of genomic binding sites and share the same consensus sequence. In particular, CTCF KO impairs SCC1 binding.

Does cohesion contribute to CTCF enhancer blocking function?

Reporter assay with pIHLIE, which is known to be responsible for the insulator sequence. By removing CTCF, the luciferase activity increases. Nothing happens by impairing sister chromatids link through a drug, Sororin. The insulator function of the H19 ICR requires CTCF binding as well as cohesin binding to DNA, but not the establishment of cohesion.

Cohesin complexes co-localize with CTCF insulator protein and are required for it to block enhancer sequences. CTCF can slide on DNA and when it reaches an already bound CTCF it stops there → functional to repress enhance function.

Herold *et al.*, *Development*, 2012

Does cohesin have anything to do with transcription regulation? Upon CTCF insulator protein (orange) binding to its DNA consensus sequence, the cohesin ring may tether two DNA double

3.1. 7- TRANSCRIPTIONAL CONTROL IN CANCER




Figure 3.5: Screenshot 2022-10-14 at 19.50.44.png




Figure 3.6: Herold *et al.*, *Development*, 2012




Figure 3.7: Screenshot 2022-10-14 at 12.10.46.png

3.1. 7- TRANSCRIPTIONAL CONTROL IN CANCER




Figure 3.8: Screenshot 2022-10-14 at 19.52.56.png

strands (red-blue helices) by encircling them. Thus, **cohesion-CTCF complexes could shield genes from the effect of enhancer sequences**, regulating gene expression, by impacting genome organization.

CTCF binding motifs tend to interact with each other forming a *chromatin loop*. During interphase, DNA is not condensed as in a canonical chromosome, each chromosome forms territories with hierarchical distribution of 3D folding. Different territories can overlap with each other, depending on the extent of histone modifications. We find compartments, territories and 3D folding of chromatin made by loops. Loops are possibly obtained thanks to the action of cohesins: in **loop extrusion**, a cohesin can slide on DNA for circling 2 ds filaments, until it reaches CTCF in a specific direction. The directionality of CTCF DNA sequences at the loop boundaries indicates the presence of a “tracking” mode for DNA loop formation instead of a simple 3D diffusion.

The hierarchical model of chromatin organization impacts gene regulation:

- linear chromosome map
- local 3D folding: local folding brings convergent pairs of CTCF sites in close spatial proximity fostering the contact between the enhancer and the target promoter
- segmentation into TADs: topologically associated domains (TADs) are self associating chromosome segments with high frequency of DNA interaction within them. TADs folding packages enhancers and promoters from the same domain while insulating them from regulatory elements of neighbouring domains.
- compartmentalization of the chromosome territory: euchromatin and heterochromatin compartments. The same compartment can also include DNA from different territories/chromosomes. Compartment A and Compartment B can be subdivided in subcompartments with distinct patterns of histone modifications.

Most TADs are constrained within CTCF-cohesin boundaries and may consist of a single or multiple DNA loops called insulated neighborhoods (or loop domains, or sub-TADs).

The sequences that are within a loop are interacting with each other with higher frequency as compared with canonical interaction rates.

The 3D structure of the genome leads to TAD (topologically associated domains), characterized by a high frequency of DNA interaction within them. Compartment A (euchromatin) and B (heterochromatin) can be subdivided in subcompartments with distinct patterns of histone modifications.

Most of the times, TAD consists of one *insulated neighbourhood* (1 loop). We can also find other cohesins inside the same TAD, resulting in *nested insulated neighbourhoods* or *two insulated neighbourhoods*. 90% of enhancer promoter interactions occur within neighbourhood boundaries in human

3.1. 7- TRANSCRIPTIONAL CONTROL IN CANCER




Figure 3.9: Screenshot 2022-10-19 at 08.48.41.png

ESCs and T cells. However, promoters and enhancers do not exclusively interact with each other, as they interact also with other sequences in the same loop.

Chromatin conformation within TADs is highly variable from cell to cell and contacts between DNA loops are dynamics.

3.1.0.2 Chromosome Conformation Capture (3C)

This method is used to verify whether distant sequences are interacting in their 3D folding. 3D conformations at the regional, chromosome and whole genome levels can be inferred by calculating the number of ligation junctions between genomic loci.

It is required to have information on all sequences of interest. It is possible to apply inverse PCR: we circularize and amplify from known primers a piece of unknown sequence. In order to test a bigger region, we can use specific primers and verify which sequence is mapped where (computational analysis).

ChIA-PET: which protein is mediating the interaction among two sequences? Use antibody for the protein of interest e.g. CTCF, pull down cross linked, digest and sequence.

Lastly, in Hi-C approach there is a fill in of the extremities of the restriction sites with biotin and direct sequencing → higher throughput.

3.1.0.3 Hi-C approach

1. HindIII restriction enzyme
2. Fill extremities and mark with biotin
3. Ligate (NheI)
4. Purify and shear DNA; pull down biotin
5. Sequence using paired-end

A Hi-C map, or **contact matrix**, is a list of DNA-DNA contacts produced by a Hi-C experiment. Spatial proximity maps of the human genome generated with Hi-C at a resolution of 1 megabase. Each pixel represents all interactions between a 1-Mb locus and another 1-Mb locus.

Lieberma-Aiden *et al.*, *Science* 2009

3.1. 7- TRANSCRIPTIONAL CONTROL IN CANCER




Figure 3.10: Lieberma-Aiden *et al.*, *Science* 2009




Figure 3.11: Lieberma-Aiden *et al.*, *Science* 2009

Changing restriction enzyme, a similar pattern is observed. The closer two sequences are in linear form, the higher their contact probability (frequency of interaction).

The probability of contact decreases as a function of genomic distance on chromosome 1. Interchromosomal interactions are depleted relative to intrachromosomal interactions. The level of interchromosomal contact differs for different pairs of chromosomes. This suggests that the chromosomes form defined territories, with an overall frequency of interaction.

Depending on the chromosome, we can find preferential contacts. Example: 20-21-22 region. In low resolution, we observe conserved interaction for synthetic or orthologous sequences.

Each chromosome can be decomposed into two sets of loci (arbitrarily labeled A and B) such that contacts within each set are enriched and contacts between sets are depleted. Regions tend to be closer in space if they belong to the same compartment (A versus B).

Bimodal pattern in eigenvector → either A or B compartment.

3D-FISH to probe four loci (L1, L2, L3, and L4) on chromosome 14 that alternate between the two compartments (L1 and L3 in compartment A; L2 and L4 in compartment B).

Lieberma-Aiden *et al.*, *Science* 2009

- Compartment B showed a consistently higher interaction frequency at a given genomic distance

3.1. 7- TRANSCRIPTIONAL CONTROL IN CANCER




Figure 3.12: Screenshot 2022-10-19 at 09.10.50.png

than pairs of loci in compartment A, suggesting that it is more densely packed.

- Compartment A correlates strongly with the presence of genes, higher mRNA expression, and accessible chromatin, as measured by DNase I sensitivity.
- Open and closed chromatin occupies different compartments in the nucleus.
- Such partitioning of the human genome was obtained based on the contact frequency of millions of loci at 1 Mb resolution

3.1.0.4 Optimization of Hi-C approach

Digestion *in situ*, permeabilize nuclei from cell and without lysing them introduce restriction enzyme cutting 4 nucleotide bases → 1kb resolution, proximity ligation performed in intact nuclei (reducing the frequency of spurious contacts).

We can divide a compartment in 6 subcompartments: A1,A2,B1,B2,B3 and B4. The genomic and epigenetic content is different: different density of active genes, CG richness, epigenetic marks,... If we increase the resolution within subcompartments, we find frequently interacting regions, which are called domains:

- *loop domains* (90% bound by TFs, they are also called “anchor sites”)
- *ordinary domains or compartment domains*

Depending on the resolution, we can define subcompartments or domains TADs.

Chromosome compartments are formed by aggregation of multiple domains with similar biochemical or functional properties. In literature some studies indicate “sub-TADs” or “insulated neighborhoods” to refer to domains identified by high-resolution Hi-C as being smaller than the domains TADs, either ordinary or loop domains.

3.1. 7- TRANSCRIPTIONAL CONTROL IN CANCER




Figure 3.13: Screenshot 2022-10-19 at 09.11.30.png

The frequency of interaction can also be depicted as a linear genomic coordinate. A Hi-C map can be integrated with ChIP-seq and RNA-seq data to assess the complexity of the domains identified by low resolution data.

The identification of TADs is highly dependent on the resolution of the Hi-C data and the scale at which the data are analysed

Rowley and Corces, *Nature Rev Genetics* 2018

Some CTCF loops encompass active and inactive domains.

Dixon *et al.*, *Mol Cell*. 2016

Given the high frequency of interaction, we can observe co-regulation favouring. Also, since different TADs do not contain frequently interacting genes, a TAD could feature enhancer blocking. Boundary function: ability of repressing the spreading of heterochromatin. Finally, repressing transcription from one TAD to another.

Conclusions:

- Genomes are partitioned into ‘contact domains’ (ordinary domains or loop domains), or TADs, with median length of 185 kb, that share similar chromatin states and tend to associate with each other forming subcompartments (some people refer TADs to the subcompartments)
- CTCF and the cohesin associate with loop domains and are found at over 86% of loop anchors.
- The pair of CTCF motifs present at the loop anchors occurs in a convergent orientation in >90% of cases
- Loops frequently link promoters and enhancers, correlate with gene activation, and show conservation across cell types and species (up to 75% are conserved between cell lines, and 50% between mouse and human orthologous genomic regions)

Insulator:

3.1. 7- TRANSCRIPTIONAL CONTROL IN CANCER




Figure 3.14: Rowley and Corces, *Nature Rev Genetics* 2018




Figure 3.15: Dixon *et al.*, *Mol Cell*. 2016

3.1. 7- TRANSCRIPTIONAL CONTROL IN CANCER

Enhancers and genes generally interact within the context of the CTCF-CTCF loops which form insulated neighborhoods that constrain interactions between regulatory elements and genes. This structure helps explain why enhancers generally control only a limited number of genes despite having an ability to function in either orientation and at long distances.

Do enhancers and promoters randomly interact within the same loop domain? Probably not, since single CTCF loops can contain both active and inactive genes.

Enhancer-gene interactions occur in insulated neighborhoods by synergic activity of Mediator and Cohesin, and not CTCF.

Mediator and cohesin physically and functionally connect the enhancers and core promoters of active genes within DNA loop domains in murine embryonic stem cells. When the transcription activators bind mediator, the mediator complex undergoes a conformational change, and this activator-bound form of mediator binds cohesin and its loading factor Nipbl, which all contribute to gene activity and DNA looping. Mediator and cohesin co-occupy different promoters in different cells, thus generating cell-type-specific DNA loops linked to the gene expression program of each cell.

There are different binding sites for cohesin mediator and cohesin CTCF. Distinct overlapping pattern in interaction sites, depletion by shRNA results in a very similar gene expression.

Co-IP:

1. lysate and wash
2. add antibody-immobilized agarose resin
3. precipitate immune complexes and wash
4. analysis by Western blot (nuclear extract vs Co-IP with IgG control)

Adapt Co-IP with ChIP: protein in chromatin complex, instead of extracting RNA de-crosslink and run protein on a gel.

Co-IP results indicate that Cohesin and Mediator interact. Chromosome Comformation Capture (3C) analyses confirmed DNA looping between promoters and enhancers of active genes. Depleting cohesin, frequency of interaction is disrupted, similar as Mediator 12.

Mediator and cohesin physically and functionally connect the enhancers and core promoters of active genes within DNA loop domains in murine embryonic stem cells

When the transcription activators bind mediator, the mediator complex undergoes a conformational change, and this activator-bound form of mediator binds cohesin and its loading factor Nipbl, which all contribute to gene activity and DNA looping. Mediator and cohesin co-occupy different promoters in different cells, thus generating cell-type-specific DNA loops linked to the gene expression program of each cell.

3.1.0.5 Promoter-Enhancer Communication Occurs Primarily within Insulated neighbourhoods

Computational analyses of published CTCF and Smc1 ChIA-PET datasets enabled identification of insulated neighborhoods encompassing 9,407 protein-coding genes of which 3,929 were transcriptionally active in mouse ESCs.

Sun et al., 2019

3.1. 7- TRANSCRIPTIONAL CONTROL IN CANCER




Figure 3.16: Sun et al., 2019

The sites of co-binding of cohesin and CTCF define *DNA loops boundaries*. We can recognize promoters by TAF2 Hac, POL II (not much Med26, repressive).

Enrichment at the boundaries, functional meaning has not yet been defined. Group promoters in quartiles (Q1-Q4) according to efficiency of transcription. The extent of interaction in loops is not necessarily dependent on the frequency of interaction. Capture Hi-C showed that almost 80% of promoter-interacting loci are constrained within the insulator or at the boundaries; these interactions do not correlate with transcription levels.

Distribution of the indicated proteins binding and promoter Hi-C interactions in insulated neighbourhoods in different RNA expression quartiles.

Promoter sequences form loops predominantly within the insulated neighborhood, in particular with enhancers and boundaries. Are the enhancer function and gene regulation constrained within the same insulated neighborhood? Is it possible to interfere with the function of specific enhancers and test whether it has an effect on genes inside and outside the insulated neighborhood?

Can the Mediator complex be removed from specific genes? They generated a sequence with promoter and TF binding site, anchored to a magnetic bead. Test with Western blot the binding of the protein. The transcription factor estrogen-related receptor b (Esrbb) directly interacts with the Mediator complex. Downregulating Esrbb would impair Mediator binding to specific enhancers, deregulating expression of distinct target genes.

Indeed, Esrbb knock down can be used to deplete Mediator, inactivate enhancers and downregulate target genes.

Now that a system to inactivate enhancers is in place, the authors can test whether enhancer function is constrained within insulated neighborhoods. 222 insulated neighborhoods contained genes downregulated more than 2 folds upon Esrbb depletion. Transcription regulation is largely constrained within insulated neighborhoods, and it involves TF-mediator interactions. Is this regulation directly related to promoter- enhancer looping?

[ho perso 2 minuti]

Depletion of Mediator causes loss of PIC assembly, same procedure as before.

Chapter 4

TCIC

4.1 13- Transcriptional Control in Cancer

4.2 Targeting transcription in cancer

In order to perform transcription targeting in cancer, we first need to understand which genes are driving tumorigenesis.

4.2.0.1 Age-related remodelling of oesophageal epithelia by mutated cancer drivers

Biopsies from cancer (red) and non-cancer (green) sites from 58 y.o. male with risk for esophagus cancer (smoking and drinking heavily). By looking at the mutational burden, cancer samples has a higher MCF (mutant cell fraction). The normal biopsies showed several mutations too. If we look closer, mutations are hitting driver genes e.g. NOTCH, TP53. Cancer samples' mutations are overlapping to a good extent and are present at a higher degree. In normal tissues we have *independent mutations*, which suggests that independent clones are present in a normal epithelium.

Yokoyama et al., Nature 2019




Figure 4.1: Yokoyama et al., Nature 2019

4.2. TARGETING TRANSCRIPTION IN CANCER




Figure 4.2: Yokoyama et al., Nature 2019

Divide patient samples in low and high risk, in normal tissues. The number of mutations per sample increases with risk and over time. By analyzing the mutation, 4 mutational signatures were identified: e.g. APOBEC is responsible for globulin production, should be restricted to lymphocytes , C→T mutation.

Yokoyama et al., Nature 2019

Normal tissues can accumulate mutations to an extent dependent on lifestyle and age.

Single cell sequencing analysis: the mutation number in colonies from low-risk individuals linearly increases with age with an annual increase of 41.5 mutations per genome per year.

Driver genes are mutated in PNE although with different frequencies as compared with cancer samples and there are substantial differences in the major drivers between PNE and ESCC. Most of the PNE samples from high-risk individuals (62 out of 64, 97%) contained one or more driver mutations. The positivity of driver mutations was 74% (69 out of 93) of all samples from low-risk individuals.

Spatial distribution and mutational composition of clones within the same biopsy:

- Young individuals: small number of shared mutations with small MCF. Limited number of driver-mutant clones. During development to early adult life stem cells and their progenies spread giving rise to **somatic mosaicism** more than positive selection.
- Elderly individuals: shared mutations and MCF markedly increase. Driver-mutant clones increase in number and size, a trend which is enhanced with lifestyle ESCC risk. Positive selection may be ongoing.

In young individuals we observe a mosaicism of small mutations, while advancing with age we can acquire more mutations which might lead to cell proliferation increase and higher probability of new mutations.

Yokoyama et al., Nature 2019

Some mutations can occur early on in life and they accumulate on specific proliferative pathway they might lead to cancer or not.

80-year-old high-risk man: Divergent clones populating a small epithelial region originated from a single stem cell with a NOTCH1 mutation almost 80 years previously. Positive selection lead to the fixation of 4 driver mutations and subclones formation. 70-year-old high-risk man: Clonal evolution initiated in a stem cell with a TP53 mutation at the age of about 13 years which persisted without evolving to cancer. Meanwhile other driver mutations were acquired.

4.2. TARGETING TRANSCRIPTION IN CANCER




Figure 4.3: Yokoyama et al., Nature 2019

Conclusions

Mutations inevitably occur in normal cells and accumulate during aging, their frequency depends on lifestyle risks. Such mutations may be positively selected (driver mutations), favoring changes that are beneficial to the individual cells, generating clones. These clones must acquire a number of specific driver mutations to transform generating cancer cells. Normal cells can become cancerous when the “right” combination of driver genes has been mutated and/or deregulated. Somatic evolution is not a linear road towards cancer, the clone size, the specific mutations and the tissue context may slow down the tumorigenic process or boost it. Tissues differ substantially in their susceptibility to specific oncogenic events and barriers to tumor formation are tissue specific due to a number of variables, including:

- Tissue-specific oncogenic function of a cancer drivers
- Cell-extrinsic factors such as cell-cell signaling
- The cell of origin and its differentiation status

With age, the spreading of mutant clones within tissues may progressively compromise the tissue contributing to aging, cancer and other diseases.

The same pattern was observed in colorectal tissue and especially skin, which has a high burden of somatic mutations.

Standard chemotherapy relies on targeting proliferating cells with alkylating agents. We can also apply precision therapy to certain oncogenes, but this approach should take into account that multiple mutations are present. Over the years, it was observed that if the expression of a target oncogene is repressed, we observe growth inhibition and tumor regression.

Cancer cells can become addicted to the expression of specific oncogenes

Important bias: we are inducing tumorigenesis by inducing overexpression of a single gene, which is not what happens physiologically. However, we know have in clinics drugs targeting different proteins and able to induce tumor regression. One of the first compounds developed was Imatinib, meant to target a kinase fused in CML. Roughly 53 out of 54 patients were cured in phase I clinical trial. All the targets hit by target therapy drugs are enzymes, most of them kinases.

Cancer cells tend to lose cellular functions which are not essential to cell viability or do not increase cellular fitness. This is due to the *genetic drift* determined by the mutational burden, epigenetic modifications, and tumor microenvironment. The silencing of redundant functions and pathways

4.2. TARGETING TRANSCRIPTION IN CANCER




Figure 4.4: Screen Shot 2022-11-04 at 11.25.54.png

can render cancer cells more susceptible to perturbations. If we hit a particular pathway in a cell, we can impair a function which was previously regulated by multiple pathways → synthetic lethality.

If the domain changes e.g. accumulation of mutations on oncogene, cancer cells can develop resistance to target therapies. The same happens with new mutations on alternative pathways.

Targeted therapeutics generally lead to resistance

Transcriptional regulators are essential effectors of the transcriptional program imposed by oncogenic drivers, also called transcriptional drivers.

RTK growth factor, frequently hit by mutations in cancer. Resistance can arise through the persistence of downstream pathway or parallel signaling transduction. This occurs as pathways converge to the same effectors, which are either co-factors regulating transcription or transcription factors. E.g. MYC or beta-catenin, which are also called *transcriptional drivers*.

Example: MYC inhibition eradicates K-RAS (driver oncogene) driven lung cancers in mice.

The consequences of oncogene inactivation for the reversal of tumorigenesis depend on the type of tumor and the genetic context. E.g. if we remove MYC from MYC driven lymphoma, we observe apoptosis of lymphoma cells. In hepatocellular carcinoma, the re-expression of MYC leads to restoring cancer. Cancer cells can escape dependence on oncogenes by acquiring other genetic events.

4.2.0.2 Key points

Cancer is caused primarily by genetic mutations and is initiated and maintained by recurrent driver mutations. Cancer cells genome undergoes a constant genetic drift. Transcription deregulation is a hallmark of cancer, as cancer cells inevitably undergo transcription rewiring. Dysregulated transcriptional programs fuel tumorigenesis. Cancers can remain addicted to the oncogenes that have driven tumorigenesis and/or to the transcriptional drivers (definitive cancer drivers). Dysregulated transcription also creates transcriptional dependencies which are not typically identified by cancer genome sequencing. **Transcriptional addiction** in cancer can be harnessed for therapeutic intervention.

Resistance to targeted therapy can occur by activating *alternative signaling molecules* and pathways converging on the same transcriptional regulators or by *acquiring mutations* on the targeted gene.

4.2. TARGETING TRANSCRIPTION IN CANCER




Figure 4.5: Gonda and Ramsay, *Nature Review Mol Cell Biology*, 2015

Transcriptional regulators act as effectors of the oncogenic drivers. Cancer cells can become as "addicted" to these effectors as they are to the oncogenic drivers.

The complexity of TFs networks renders resistance mechanisms difficult to be developed.

Transcription factors interact in complex networks, also involving other transcription regulators. It is unlikely that any TF, or non-TFs transcriptional regulators such as CBP-p300, BRD4, can be completely replaced by another. It is more difficult to bypass this particular targeting.

Gonda and Ramsay, *Nature Review Mol Cell Biology*, 2015

Targeting transcription regulators will have a lower likelihood of emergence of resistance than targeting intracellular signaling pathways, also because multiple pathways can converge on the same transcription regulator. Inhibiting a specific transcriptional program may impact more than one oncogenic signal. The main issue is to identify transcriptional drivers, which might not be affected by mutations; it is required to perform wet lab experiments. Furthermore, target mutations can still emerge as resistance mechanism.

4.2. TARGETING TRANSCRIPTION IN CANCER




Figure 4.6: Bywater *et al.*, *Nature Review Cancer-* 2013

4.2.1 Target transcription in cancer

There exist numerous ways to target transcription in cancer:

- interaction with co-factor
- interaction with ligand → most effective mechanism, clinical trials
- PTM
- TF-TF interaction
- impairing recruitment to responsive elements

The mechanism of action can be PROTAC or monomeric degradation: they bind their own target and promote degradation. The **monomeric degrader** can alter 3D structure to make accessible to proteosomal degradation. **PROTAC** has a domain for E3 ligase, which leads to the recruitment of protease. In principle these molecules can interact with any region of the protein e.g. epitope, AA sequence (not necessarily domain). Once the protein is degraded, the molecule is still around and can be recycled to degrade other proteins (1:1 stoichiometry is not required).

Bywater *et al.*, *Nature Review Cancer-* 2013

The Mediator and other complexes are controlled by kinases, so we can foster their inhibition.

THZ1 interacts with the ATP binding pocket of CDK-7, covalent bond with Cys321. In the study the THZ1-R,R was used as a control, as it should not achieve Cys binding.

By pulling down THZ1, we can visualize CDK7 activity: by increasing the amount of THZ1, the competition with bio-THZ1 is overcome and CDK7 expression is inhibited. RNAPII phosphorylation is impaired in vitro with high amounts of THZ1. If the experiment is performed with mutated C312S, phosphorylation of Pol II is not inhibited anymore.

Washout experiment: treat compound, wash and let cells grow without the compound. In this case CDK7 inhibition persists, since it is irreversible thanks to covalent binding.

THZ1 treatment shows broad antiproliferative activity in cancer cell lines by modulation of transcription.

4.3. 15- TRANSCRIPTIONAL CONTROL IN CANCER

High throughput screening of cell lines in micro plates to test cell proliferation shows that T-ALL cells are particularly sensitive to small perturbations in transcription and CDK7 kinase function. Instead BJ fibroblasts and RPE-1 were not affected.

Bioluminescent xenografted mouse model confirmed efficacy of THZ1 in blocking tumorigenesis of the human T-ALL cell-line KOPTK1. No toxicity of the compound was observed in mice. High doses of THZ1 were required to impair proliferation of non transformed cells.

Why do cancer cells and in particular T-ALL cells are more sensitive to CDK7 inhibition than non cancer cells? By applying 250 nM of THZ1 we observe the reduction of transcription of all genes. If we lower the concentration at 50 nM, only a subset of genes will be impacted e.g. TAL1, GATA3, RUNX1 → super enhancer region, these factors autoregulate their own gene expression while simultaneously regulating many other genes.

RUNX1 forms a core regulatory circuitry with TAL1 and GATA3 transcription factors that have prominent roles in leukaemia biology

Takehome message:

Targeting transcription is a promising anticancer approach which can be achieved by CDK7 inhibition. Transcription rewiring of cancer cells can be triggered by acquisition of super-enhancers driving oncogene expression and tumorigenesis. Super-enhancer driven oncogenes lead to transcription addiction generating transcriptional dependencies which can be used for therapeutic intervention. Cancer cells require continuous active transcription which renders them more sensitive to transcription targeting therapeutics. In particular oncogenic drivers like MYC and RUNX1 have short mRNA and protein half-lives and depends on continuous transcription. Genomic sequences may not suffice to identify driver oncogenes and cancer vulnerabilities.

4.3 15- Transcriptional Control in Cancer

4.4 BRD4

BRD4 is a member of the Bromodomain and Extraterminal (BET) family along with BRD2, BRD3 and BRDT. It is a histone acetyltransferase that evicts nucleosomes from chromatin. In particular, BET inhibitors impair super-enhancer driven oncogene expression. ****

4.4.0.1 Selective inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

Super-enhancers associated genes were expressed at higher levels than enhancer-driven genes and specifically in mieloma cell line. The majority of super enhancer associated genes were previously shown to be involved in mieloma tumorigenesis e.g. MYC, CCND2. Treatment of MM1 cells with Brd4 inhibitor JQ1 resulted in reduced levels of BRD4 at enhancers and promoters.

JQ1 treatment lead to more pronounced reduction of BRD4 enrichment at super- enhancers showing almost complete loss of BRD4; in particular, super-enhancers are more sensitive to BRD4 inhibition than regular enhancers. MYC is among the most rapidly depleted genes upon BRD4 inhibition.

Genes associated with super-enhancers showed greater decrease in RNApol II at gene body than the ones associated with enhancers.

4.5. YAP/TAZ




Figure 4.7: Screen Shot 2022-11-13 at 19-35-28.png




Figure 4.8: Screen Shot 2022-11-13 at 19-40-17.png

- Cancer cells can acquire super-enhancers (SE) as mechanism to drive oncogene expression
 - SE are characterized by disproportionately high levels of BRD4 and Mediator, interacting with each other and with multiple cofactors
 - SE are highly reliant on cooperatively interacting factors and lose activity more rapidly (than enhancers) when the levels of SE-bound factors are reduced
 - BRD4 inhibition leads to preferential disruption of SE driving critical oncogenes in cancer cells

The molecular details underlining cancer cells addiction to BRD4 are being unveiled.

4.5 YAP/TAZ

The transcriptional coactivators YAP (Yes-associated protein)/ TAZ (transcriptional coactivator with PDZ-binding motif) and their interactors.

The **HIPPO signalling** regulates YAP/TAZ and epithelial architecture and cell polarity are inhibitors of YAP/TAZ → EMT triggers inactivation of the Hippo cascade and YAP/TAZ activation.

4.6. TEAD




Figure 4.9: Screen Shot 2022-11-13 at 19-41-35.png




Figure 4.10: Dupont et al., Nature 2011

Mechanical signals are ubiquitous, targeting every cell in every tissue. Mechanotransduction converge on YAP/TAZ in multiple cellular contexts.

YAP and TAZ are nuclear effectors of mechanical signals exerted by ECM and cell shape:

Dupont et al., Nature 2011

The process of tumorigenesis is accompanied by collagen crosslinking, ECM stiffening, and increased focal adhesions. YAP/TAZ activity is controlled by cell shape and polarity through the cytoskeletal structure which also senses the topology and the rigidity of the extracellular matrix.

Cells probe the physical features of the microenvironment through integrins and adhesive proteins responding to extracellular forces by adjusting their tensional state through the cytoskeleton activity. Physical and mechanical cues transmitted by the extracellular environment (i.e.: stiffness of the ECM) reach the nucleus at least in part by YAP/TAZ activation.

YAP/TAZ interact with the TEAD transcription factors to regulate gene expression.

4.6. TEAD




Figure 4.11: Screen Shot 2022-11-13 at 19-48-01.png

4.6 TEAD

TEAD is regulated by Hippo, Wnt, TGF-beta and EGFR pathway and is responsible for controlling drug resistance, metastasis, EMT and cancer stem cells. TEAD-driven transcriptional targets include well-established genes that are involved in cell growth, proliferation, and tissue homeostasis. YAP/TAZ drive several key attributes of cancer cells.

4.6.1 YAP/TAZ/TEAD

Mapping YAP/TAZ/TEAD associations with chromatin in breast cancer cells reveals that these regulators associate with active enhancers. Hi-C analyses predict about 3000 genes regulated by YAP/TAZ/TEAD. 3C analyses confirmed YAP/TAZ/TEAD binding to MYC and TOP2A enhancers.

YAP/TAZ are required for activation of MYC and TOP2A enhancers.

YAP/TAZ-depleted cells stop proliferating and accumulate in G1.

TEAD depletion phenocopies YAP/TAZ depletion → TEAD is determinant for YAP/TAZ induced proliferation. Most YAP/TAZ motifs contained both TEAD and AP-1 motif.

Requirement of AP-1 for YAP/TAZ/TEAD induced transcription program tumorigenesis.

YAP/TAZ interact with the TEAD transcription factors to regulate gene expression. AP-1 enhances YAP/TAZ/TEAD transcription program and tumorigenesis

BRD4 inhibition impacts the YAP/TAZ transcriptional program in the MDA-MB-231 breast cancer cell line → **Brd4 is required for YAP/TAZ-mediated transcriptional regulation**. In addition YAP/TAZ are required for BRD4 recruitment to chromatin.

Conclusions:

- YAP/TAZ and BRD4 associate physically and functionally in breast cancer cell lines

4.7. 17- TRANSCRIPTIONAL CONTROL IN CANCER

- YAP/TAZ-BRD4 complex confers a transcriptional advantage to a broad YAP/TAZ targets the expression of these genes can be targeted by BET inhibitors
- Super-enhancers consist of YAP/TAZ-occupied enhancers showing strong enrichment of BRD4, high expression levels of regulated genes and higher sensitivity to BET inhibitors than average
- Oncogenic effect of BRD4 in association to YAP/TAZ offers a new perspective: to stratify patients which are more likely to benefit from BET inhibitors, alone or in combination with other drugs
- Development of new therapeutic approach around YAP/TAZ-BET interaction surfaces

→ YAP/TAZ represent ideal candidates to mediate cancer-specific transcriptional addictions and potential drug targets ****

4.7 17- Transcriptional Control in Cancer

Recap

[...] copy from slides

The inhibition of BRD4 could represent an important mechanism to target.

If we analyze tumorigenic mechanisms *in vivo* and *in vitro* we will observe different results: processes dictated by the microenvironment will significantly impact on the tumorigenic potential of cancer cells.

Binary pan-cancer: YAP/TAZ are upregulated oncogenes. Cancers that do not express YAP/TAZ can silence its expression, as it will lead to cell death and differentiation. The effect of YAP/TAZ all depends on the transcriptional program. It is possible to impair YAP/TAZ through targeted therapies e.g. Tyr kinase inhibitors or Ser/Thr kinase inhibitors; however we must be careful, as resistance can arise. When the transcriptional program is inhibited, tumor suppression is observed. In the case of YAP^{off} cancers we observe the expression of MYC, which could be targeted. If we manage to re-express YAP/TAZ, they will bind to TEAD and bHLH activating genes promoting adhesion and cell differentiation, always resulting in tumor suppression.

4.8 Nuclear receptors

Nuclear receptors are transcription factors which mediate transcription regulation upon receptor-specific ligand binding. Usually NR are found bound to DNA in the nucleus or to other proteins in the cytoplasm. In most of the cases they are hetero or homodimers. Nuclear receptors share a common architecture - very conserved modular structure composed by 2 transactivator domains, DNA binding domain and C terminus ligand binding domain (11 helices forming a pocket, 12th helix outside acting as a pocket closure) - and functional behavior. NR are involved in many processes and in different forms of cancer e.g. estrogen receptor alpha ((ER α)).

ER α is associated with proliferation and development and cells for the formation of tissues and organs in women. ER β has the opposite function, it is repressing proliferation. ER α is expressed in mammary glands and uterus., ER β colon or immune system cells. It is still unclear how the two behave so differently, probably specific TF interaction.

4.8. NUCLEAR RECEPTORS




Figure 4.12: Screen Shot 2022-11-18 at 11-11-12.png

4.8.1 Estrogen receptor α

Estradiol induces dimerization of ER and binding of the dimer to ER response elements (EREs). ER α binds to HSPs and when estradiol is met we observe the conformational change leading to ERE binding. For achieving a complete activation of the NR, PTMs are required e.g. Cdk7 targets S118 for phosphorylation.

The main antagonists of ER are known as **SERM** and **SERD**. The first target therapy for ER, *Tamoxifen*, was developed in the late 60s. Tamoxifen belongs to SERM, modulator interacting with ER, impairing the ability to interact with the binding site. Once ER binds it cannot recruit co-regulators, its transcriptional action is shut down. Short term Tamoxifen treatment does not show high survival rates, but longer times expose patients to side effects e.g. acts as agonist for ER in endometrial cells. Other drugs from SERM family act similarly e.g. Raloxifene and Bazedoxifene. In addition to SERM, we have ER degraders from SERD family → through degradation PTMs e.g. sumoylation. Fulvestrant is a steroid derivative molecule (quite different from Tamoxifen), not water soluble so needs to be injected in muscles.

The two major strategies for therapeutic targeting of hormonal signaling in breast cancer are *direct antagonism* of the ER and *estrogen deprivation*. Aromatase inhibitors can avoid estradiol production in order to deactivate ER activation.

4.8.2 ER α) in breast cancer

- Nearly 75% of breast cancers are driven by ER α -mediated transcriptional activity
- Estrogen deprivation and direct antagonism of ER represent the two major strategies for therapeutic targeting of ER+ breast cancers

4.8. NUCLEAR RECEPTORS




Figure 4.13: Screen Shot 2022-11-18 at 11-06-54.png




Figure 4.14: Screen Shot 2022-11-18 at 11-14-09.png

4.8. NUCLEAR RECEPTORS

- More than 20% of patients develop resistance to anti-estrogens and relapse with metastatic disease

4.8.2.1 Mechanisms provoking breast cancer drug resistance

Clinical sequencing of 11 metastatic ER-positive breast cancer cases before and after therapy showed that **ESR1 mutations** were not present at an earlier stage, indicating that they were acquired after endocrine therapy. Tumors had survived estrogen targeting or deprivation treatments by acquiring ESR1 mutations.

ESR1 alterations are focused on H12 of the LBD. Analyses of 390 ER-positive breast cancers (primary tumors, before hormonal treatment) from the TCGA revealed no LBD-disrupting mutations of ESR1.

ESR1 with acquired mutations encode constitutively active proteins functioning in the absence of ligand → resistance mechanism. The mutated ESR1 variants are active in the absence of estrogen and continue to be responsive to direct ER antagonists. These mutations might not have been arisen under selective pressure of anti-estrogen treatment but rather in the context of an estrogen deprivation setting, such as treatment with aromatase inhibitors and/or oophorectomy. 67.4% of the ESR1-mutant metastatic patients had prior exposure to an aromatase inhibitor.

The presence of a somatic mutation in the LBD of ESR1 does not necessarily imply constitutive activity. The most frequent mutation is D538G. Most mutations were activating ER in the absence of estradiol. ER mutants show increased S118 and S167 steady state phosphorylation.

Fulvestrant (ICI) was able to inhibit the activity of all of the mutants which however showed significant differences in sensitivity to the drug. Y537S mutants displayed 70-fold higher IC99 than WT ER, while E380Q and S463P showed 2-fold higher IC99. Fulvestrant fully inhibited the growth of the WT-, E380Q-, and S463P expressing tumors while nearly completely inhibiting the growth of D538G tumors. The Y537S-expressing tumors, however, continued to grow in the presence of fulvestrant, albeit more slowly than in untreated controls, AZD9496 was able to completely inhibit their growth.

These findings are consistent with results from a subsequent clinical trial identifying the ER α Y537S as an acquired mutation promoting resistance to fulvestrant treatment. Patients previously progressing on endocrine therapy were enrolled for either palbociclib plus fulvestrant or placebo plus fulvestrant treatment, demonstrating an improvement in median PFS from 4.6 to 11.2 months with the addition of palbociclib to fulvestrant. Acquisition of new PIK3CA and ESR1 mutations, in particular the ESR1 Y537S mutation, in both treatment arms implicates these changes in the development of parallel mechanisms of resistance and suggest potential new avenues for treatment.

4.8.2.2 Summary

- *ESR1 gene mutations* are found in about **14% of breast cancer metastasis**
- Most ER mutations promote an activated conformation in the absence of ligand which remains permissive for ligand binding, thus a direct antagonism may be a strategy for these mutants
- Mutations behave differently in terms of ER activity and sensitivity to drugs
- Mutated-ER proteins can be inhibited by *fulvestrant* and *AZD9496*, Y537Y mutation is more resistant to fulvestrant

4.8. NUCLEAR RECEPTORS




Figure 4.15: Screen Shot 2022-11-18 at 11-59-02.png

- Mutation of Y537 site to cysteine (C), aspartic acid (D), and asparagine (N) caused receptor activation, but to a lesser degree than did the S mutant. Hence, the level of ER activation depends on both the site of mutation and the nature of the mutant residue
- Tumor genotyping of *ESR1* mutant breast cancers also revealed recurrent alterations in the PI3K/AKT pathway, cyclin D1, and FGF receptors which will likely influence the tumor addiction to ER. Combinations of antiestrogens with inhibitors of PI3K, AKT, CDK4/6, and FGFRs or other chemotherapeutic agents can represent the best treatment

4.8.2.3 ER α transcriptional program

Multiple growth factor and cytokine signaling pathways can induce phosphorylation of ER activating the receptor in the absence of estradiol, thereby promoting cell proliferation. The independence from ER is due to over activation in downstream pathway effectors.

ER α ChIP-seq analyses of tumor samples revealed 484 ER common binding regions. ER α -chromatin binding signal intensity is higher in tumors that progress towards a poorer prognosis and ultimately metastasize. The genes within 20 kilobases from the 484 ER-binding events exhibited elevated expression in the ER+ tumors, as compared to all other genes and were higher in ER+ tumors relative to ER- tumors. ER α ChIP seq revealed differential ER-binding events between patients with good outcome and patients with poor outcome or metastases.

FOXA1 motifs were enriched in ER α binding regions of tam-resistant cells while **GATA** motifs were enriched in ER-binding events of tam-responsive cells. What is driving ER reprogramming?

Mitogen treatment of MCF7 cells (EGF, IL-6, TNF-a and IGF-I) reprogrammed ER-binding events

Distinct ER-binding profiles are associated with clinical outcome of breast cancer patients. These differential ER-binding profiles are for the most part mediated by FOXA1. Upregulation of growth factor pathways (along with ESR1 mutations and changes in cofactors levels) can influence ER binding reprogramming and the consequent change in gene expression profile fuels tumorigenesis and resistance to treatment of breast cancer cells. Since ER binding to DNA is for a good part dependent on FOXA1, targeting FOXA1, instead of ER might provide an opportunity for blocking ER transcriptional activity.

4.8. NUCLEAR RECEPTORS

Half of all ER-binding regions overlap with a FoxA1-binding region. FOXA1 can open chromatin to ER. In addition, numerous ER-binding partners regulate ER transcriptional activity.

It was observed that transcriptional reprogramming is present in Y537S and D538G mutants. Y537S and D538G mutants promote the transcription of a unique set of genes not induced by WT ER upon estrogen stimulation.

The FOXA1 motif was not significantly enriched in the mutant-selective binding sites, suggesting that FOXA1 may be less essential for mutant-specific ER DNA binding. E2-independent ER recruitment in the presence of the Y537S and D538G mutations, with a redistribution of 39% and 49% of the ER binding events for the Y537S and D538G mutations, respectively. CDK7 silencing impacted proliferation of both WT-ER and Y537S expressing cells.

In principle, if we find ER enhancer RNA promoting specific cancer genes, we can target it and selectively inhibiting it.

Chapter 5

Genome instability

5.1 19- Transcriptional Control in Cancer

5.2 Transcription and genome instability

5.2.1 R-loops

RNA is quickly displaced as soon as it emerges from Pol II; during transcription RNA-DNA hybrid structure is required, but it is *transient*. It has been observed that RNA can re-hybridize with the template DNA forming **RNA:DNA hybrid** and **R-loop structures**. R-loop formation results from a competition between the nascent RNA and the non-template DNA strand to hybridize with the template strand.

Hamperl and Cimprich, DNA Repair, 2014

High G density in the non-template DNA strand promotes R-loops formation. RNA:DNA hybrids rich in RNA-G/DNA-C ratio are more stable than DNA:DNA duplex of the same sequence.

Transcription unwinding results in topological stress and generation of DNA supercoils.

- Positive toroidal supercoils: dsDNA is tightly packed
- Negative toroidal supercoils: loose DNA, predisposition to RNA insertion.




Figure 5.1: Hamperl and Cimprich, DNA Repair, 2014

5.2. TRANSCRIPTION AND GENOME INSTABILITY

Superhelical stress can favor, and be mitigated by, R-loops formation.

In highly transcribed genes we witness histone turnover, which is favored by negative supercoiling. R-loops formation inhibit nucleosomes redeposition weakening surrounding nucleosome-DNA contacts.

G-rich sequences and negative supercoiling can promote the formation of R-loops

In addition, to win competition with the non-template strand, the stability of the sequence is important → G-quadruplexes highly increase stability.

G-quadruplexes: 4 guanines interacting by hydrogen bonds (Hoogsteen) on the same plane (planar quartet). We can find parallel G4 or antiparallel G4 (based on the orientation of guanines).

R-loops are typically formed co-transcriptionally (*cis*) but formation in *trans* has been reported and expected e.g. Cas9 pathway or ncRNA with unwinding promotion.

5.2.1.1 R-loop degradation

TREX complex: mediates transcript export for splicing and translation. If we remove THO subunit, we impair trex and formation of R-loops → limiting the amount of naked RNA in the cells prevents R-loops accumulation.

R-loops are also actively eliminated by specific enzymes:

- RNase H1/2 recognize and degrade R-loops
- RNA:DNA helicases e.g. Sen1/SETX

5.2.1.2 R-loop recognition and distribution

DRIP-seq: The monoclonal S9.6 antibody revealed thousands of R-loop hotspots in human genome. R-loops can be found in:

- highly transcribed genes (as rate of transcription can influence loop formation for negative torsional stress)
- telomeres: G-rich non-template strand, C-rich template strand
- ORF: proposed function at termination sites for termination factor recruitment e.g. chromatin remodeling.

! Pull down is performed after sonication, mechanic stress on DNA → bias. A good part of the signal could be coming from dsDNA. Over the years, improvements to the method were done e.g. bisulphide for T→U, only finds RNA.

Endogenous R-loop structures are also detected by **R-ChIP**: a catalytically dead RNASEH enzyme can be expressed in cells, able to recognize but not degrade. We visualize R-loops endogenously. Bias: RNASE can be recruited on paused sites, the technique can only applied in cell lines.

R-ChIP and DRIP-seq experiments reveal R-loops enrichment at promoter regions and TSS. Approximately 60% human promoters are associated with a CGI - CGI methylation generally associates with gene silencing.

5.2. TRANSCRIPTION AND GENOME INSTABILITY




Figure 5.2: Screen Shot 2022-11-23 at 10-18-00.png

R-loops form in human CpG island promoters with G-rich sequence at the non-template strand (GC skew) regulate DNA methylation.

Example of involvement of R-loops in transcription regulation.

5.2.1.3 VIM-antisense1

VIM is an intermediate filament in mesenchymal cells (EMT process). There is a presence of a CpG island. Usually with antisense the transcription of the sense collides due to sterical hindrance (overlapping). In this case, the antisense is polyadenylated and nuclear, while the sense is cytoplasmic. The expression of the antisense is associated with down-regulation of the sense gene. Depletion of VIM-AS1 causes downregulation of the VIM gene expression caused by methylation.

The two transcripts can be visualized through FISH with different fluorophores. By combining this technique with the inhibition of transcription VIM disappears, while VIM-AS1 is more stable. This could be due to the fact that it is engaged with a R-loop structure. The genomic region between the two TSSs shows GC skew sequences.

R-loop formation is dependent on the antisense transcript. RNaseH1 overexpression inhibits VIM and VIM-AS1 expression. R-loop structures promote VIM expression by impairing nucleosome occupancy and favoring the binding of transcription factors.

Expression of antisense and R-loop associate with open chromatin

By blocking R-loops or inhibiting VIM-AS1 at FNkB TF binding sites accessibility is reduced and the recruitment of the TF at the locus is impaired.




Figure 5.3: Screen Shot 2022-11-25 at 11-49-03.png

5.2.1.4 Main findings

- loop formation by antisense RNAs at CpG island containing promoters can impair DNA methylation at these promoter sequences
- decrease nucleosome occupancy and favor binding of the transcription factor NF- κ B to the promoter of Vimentin gene promoting transcription of the sense gene

R-loops can regulate gene expression by multiple mechanisms: repressing chromatin modifiers, activating chromatin modifiers and chromatin regulating complexes. They arise naturally and have multiple physiological effects e.g. DNA repair, replication and gene expression, and are therefore tightly regulated. R-loops are generally transient and regulated by enzymatic activity; under certain conditions, R-loops become de-regulated and accumulate in cells.

5.2.2 HOTTIP-dependent R-loop formation regulates CTCF boundary activity and TAD integrity in leukemia

In vertebrates the Hox genes are located contiguously in clusters. Hox genes are expressed in a tightly regulated spatio-temporal manner during embryogenesis. They possess the homeobox domain and are divided into 4 clusters. The spatio-temporal expression is also observed in human primary fibroblast from different sites. 5C chromosome interaction highlights the presence of the *posterior domain*. Differentiated cells (distal cells from limbs) have a distinct pattern with respect to proximal cells (from lung): in distal Pol II signal and H3K4me is observed in the first HOTTIP region, while the opposite pattern is present in proximal cells (HOTAIRM1 region at 3' → lncRNA interacting with chromatin remodelling complex).

HOTTIP stands for HOXA transcript at the distal tip. HOTTIP lncRNA stimulates the transcription of HoxA genes by enforcing H3K4me3 chromatin modification.

Chromosomal looping brings HOTTIP RNA in close proximity to the HOXA genes. HOTTIP lncRNA binds to and targets WDR5-MLL complexes to the HOXA locus, leading to transcription

5.2. TRANSCRIPTION AND GENOME INSTABILITY

activation. The mutual interdependence between HOTTIP RNA and WDR5-MLL creates a positive feedback loop that maintains the ON state of the locus.

HOX genes are mutated or deregulated in different cancers and play active roles in tumorigenesis. HOXA genes are expressed in hematopoietic stem cells and progenitor cells while downregulated during differentiation. Abnormal HOXA gene activation is a common feature of acute myeloid leukemia (AML). HOXA9 and HOXA10 genes are frequently aberrantly activated in AML patients. Dysregulation of HOXA genes (e.g., HOXA9) is a driving mechanism for hematopoietic deregulation and leukemogenesis. Overexpression of HOXA9 is a poor prognostic marker in leukemia patients while its downregulation is a favorable predictor of AML patient outcome. The mechanisms regulating HOXA genes expression in AML patients is under investigation.

A transition from repressive to active chromatin is detected within the HOXA locus in AML patients. Among A7 and A9 we observe a sort of boundary, mainly regulated by insulator sequences → the CTCF binding site located between HOXA7 and HOXA9 genes may regulate the aberrant activation of the HOXA9-13 genes in AML cells.

Deletion of the CTCF binding site between HOXA7/9 genes (CBS7/9⁺⁻) alters HOXA gene expression in AML cell lines. The homozygous deletion was incompatible with cell survival, so heterozygous was used. ChIP-seq analyses of CBS7/9⁺⁻ cells show altered chromatin structure in the HOXA9-13 domain but not in the HOXA1-7 locus, consistent with a loss of boundary function. 4C-seq data indicate decreased HOXA9 interaction with proximal genomic sites.

CBS7/9⁺⁻ is important to regulate the chromatin structure and the expression of HOXA9-13 genes in AML cells

Dysregulation of CBS7/9 boundary inhibits leukemic cell proliferation and prolongs survival time of transplanted NSG mice. In addition to the local effect on chromatin marks and structure, a significant number of dysregulated genes was observed e.g. oncogenic pathways RUNX1, SOX involved in myeloid activation.

Attenuation of the chromatin boundary disrupts the active chromatin domain and perturbs oncogenic gene expression in AML, in part by disrupting the HOXA9 oncogenic pathway. The CBS7/9 boundary located at the edge of the TAD encompassing the posterior HOXA genes establishes and maintains aberrant chromatin signatures and expression of the posterior HOXA genes to facilitate myeloid leukemogenesis. The elimination of CTCF fosters the formation of aberrant protein.

Can a normal CTCF boundary be hijacked to control oncogenic chromatin domain and transcription profiles for leukemic transformation and progression?

HOTTIP^{-/-} perturbs HOXA gene-mediated oncogenic transcription program, we observe oncogene downregulation. The KO is able to recapitulate the effect of CBS7/9 on HOXA. In wt AML cells we can identify the anterior and posterior domain, in KO cells we observe a change in the posterior domain.

HOTTIP lncRNA is aberrantly expressed in a subset of AML patients and cells. NPM1-mutated (NPM1C+) or MLL-rearranged (MLLr+) AML cases (n = 76) exhibited elevated levels of HOTTIP expression. Survival rate was inversely correlated with HOTTIP expression.

Activation of HOTTIP rescues the HOXA gene chromatin defects in the CBS7/9⁺⁻ AML cells.

HOTTIP transgenic expression in hematopoiesis leads to AML-like disease and promotes hematopoietic transcription programs.

5.3. 20- TRANSCRIPTIONAL CONTROL IN CANCER

5.2.2.1 Conclusions

- HOTTIP expression alters HOXA genes containing TADs and HOXA genes expression
- HOTTIP KO affects leukemic transcription program while HOTTIP overexpression leads to AML-like disease
- HOTTIP is aberrantly expressed in AML patients

5.2.3 HOTTIP lncRNA Promotes Hematopoietic Stem Cells Self-Renewal Leading to AML-like Disease in Mice

CHIRP: reminds us of ChIP for crosslinking and sonication. Instead of using antibodies, they use specific probes for RNA of interest with tilling oligos (bp with different regions of the RNA, increased yield of the pull down). At the end of the protocol we obtain RNA.

HOTTIP interactome isolated from AML cells contains CTCF/cohesin complex and R-loop- associated proteins.

HOTTIP KO resulted in a significant reduction of R loops and HOTTIP binding sites, especially when cobound to CTCF.

No signal from GRO-Seq → HOTTIP KO disrupted CTCF and cohesin TAD boundaries containing AML oncogenes such as β -catenin (CTNNB1). At these boundary sites HOTTIP RNAs form R-loops in trans. HOTTIP-mediated R-loop formation directly contributes to CTCF boundary activity.

R-loops disruption at the CBS-u2 boundary site impairs proliferation of AML cells.

5.3 20- Transcriptional Control in Cancer

5.4 Transcription and genome instability II

5.4.1 DNA damage

Single stranded DNAs are more susceptible to chemical modifications, strand breaks, mutagen sensitivity and secondary structure than dsDNAs. Also dsDNA is undergoing spontaneous chemical modifications. Basically, any covalent bond in DNA molecule can be attacked by a water molecule. It has been estimated that there are thousands of spontaneous lesions in our cells e.g. depurination ($G \rightarrow$ sugar phosphate) or deamination ($C \rightarrow U$). Spurious methylation can occur in bases different from cytosine; when a RNA pol II passes through modified bases, we can observe a stall or the insertion of an erroneous base, leading to mutations. The addition of chemical groups occurs when bases react with oxygen species e.g. guanine + adduct radical gives 8-hydroxyguanine.

Base excision repair (BER) pathway eliminates modified bases or depurinated nucleotides.

Base excision repair

The chemical modification rate in oligonucleotides depends on cation concentration, pH, and other experimental conditions. Roughly 5% of the genome can be occupied by R-loops.

5.4. TRANSCRIPTION AND GENOME INSTABILITY II




Figure 5.4: Base excision repair

5.4.1.1 R loop modified bases

Modified bases within R-loops that are not properly repaired form nicks and breaks (this step requires dsDNA) → replication and transcription stops. R-loops accumulation associates with genome instability due to the spontaneous base modifications occurring at ssDNA and the ensuing processing events leading to nicks and breaks.

R loop repair

Thanks to R-loop displacement, BER can excise modified bases; this provokes a misaligned dsDNA, leading to breakages - especially if loops are hit by modifications - and genome instability.

R-loops can lead to nicks and breaks (DSBs) also due to the activity of the AID/APOBEC ****cytidine deaminases (catalyzed modifications). **Activation-induced cytidine deaminase** (AID) promotes somatic hypermutation and class switch recombination of immunoglobulin (Ig) genes in germinal center (GC) B cells. AID off-target activity has been implicated in malignant transformation of GC-derived B cell lymphomas.

C→U is meant to be, as cells want to induce mutation in a random manner to achieve hypervariability. In particular, several cancers are characterized by APOBEC signatures, which are a key source of mutation e.g. chromosome instability in early breast and lung cancer evolution. Not only *spontaneous* base modifications but also cytosine deamination catalyzed by **APOBECs** can lead to nicks and breaks within R-loops structures leading to genome instability.

5.4.2 Apical kinases

Cells have evolved the **DNA damage response** (DDR) in order to combat threats posed by DNA damage. Breaks are sensed by apical kinases: **ATM**, **ATR** and **DNA-PKcs**. Phosphorylated serine or threonine residues followed by glutamine (S/T-Q) S/T-Q sites are present in ATM, ATR and DNA-PKcs for autophosphorylation. They all contain a kinase domain at the C-terminal. Cancer cells and immunodeficient cells (mutated in these genes) are more susceptible to radiation, since the recognition of ds breaks is impaired → radiotherapy would result in important side effects.

ATM, ATR and DNA-PKcs require specific co-factors for their recruitment to damaged DNA. ATM is linked to a trimeric complex (MRN), where MRE11 is the endo/exo nuclease, RAD50 recognizes dsDNA and NBS1 is full of PPinteracting domain (ATM recruitment). ATR is recruited to dsbreaks when they are processed, so ssDNA bound by RPA (aspecific marker), bound by ATRIP co-factor.

Apical kinases

They are also involved in cell cycle control, DNA replication, transcriptional regulation and RNA metabolism. It orchestrates real cell response.

5.4. TRANSCRIPTION AND GENOME INSTABILITY II




Figure 5.5: R loop repair




Figure 5.6: Apical kinases

5.4. TRANSCRIPTION AND GENOME INSTABILITY II




Figure 5.7: Blackford and Jackson, *Mol Cell*, 2017




Figure 5.8: Trenner and Satori, *Frontiers in Oncology* 2019

DNA-PKcs promotes NHEJ of DSBs: DNA-PKcs phosphorylation allows the recruitment of downstream NHEJ core factors, leading to DNA-end ligation by LIG4. This pathway is fast and can be used in all cell cycle phases.

ATM activation promotes a signaling cascade on damaged chromatin. MRN recruits ATM, which can phosphorylate hundreds of different targets, which are themselves kinases → kinase cascade. The first event is the phosphorylation of H2AX, leading to gamma H2AX marker for DNA damage. MDC1 is recruited and phosphorylation, additional MRN recruitment and feed-forward mechanism. Gamma H2AX can spread megabases, self sustaining cycle enhancing the reaction to ds break. TIP60 activates ATM through acetylation.

53BP1 is an effector of DNA damage response (reaction of the cell to ds break, enabling sensing) and DNA repair mechanism (fix the break) → NHEJ activation. Among the ATM targets we have BRCA1 (scaffold molecule and ubiquitinligase) and CtIP (endonuclease), which are phosphorylated → signal for the cell to activate homologous recombination (requires the sister chromatid, S phase only).

Blackford and Jackson, *Mol Cell*, 2017

BRCA1 and 53BP1 determine the choice of repair mechanism between NHEJ and HR. The decision between NHEJ and HR is also determined by several factors including cell cycle phase, chromatin state, genetics. NHEJ is “error prone” (but not in the classic pathway, alternative one), while homologous recombination is error free.

5.4. TRANSCRIPTION AND GENOME INSTABILITY II

Trenner and Satori, Frontiers in Oncology 2019

DNA damage response integrates regulation of the cell cycle, which is blocked in order to prevent mitosis. It is necessary to allow repair mechanism to act before resuming the cell cycle. Cell cycle is regulated by CHK2 (kinase phosphorylating CDK29) and p53.

The key signal for the cell in the context of repair comes from DNA ends; telomere mask chromosome ends from being recognized as double-strand breaks.

DNA damage response (DDR) involves DNA lesion recognition followed by a signaling cascade to promote DNA repair. The effectors lead to transient checkpoint, cellular senescence and apoptosis.

The roles of **PARP1** (poly(ADP-ribose) polymerase 1) ****in detection and repair of DNA double-strand breaks are several. It is recruited to ds break and adds poly(ADP-ribose) chains. The recruitment of covalently and non-covalently modified proteins to site of DNA damage allows for repair of ssDNA nicks and breaks, sd breaks and chromatin modifications. PARP is also associated with ATM itself and is involved in HR, cNHEJ and aNHEJ. Although it is not the only activating mechanism of BRCA, it supports it to the break and lead to strand invasion and resolution.

Summarizing, defects in DSB repair e.g. loss of Xrcc4, LIG4, BRCA1 lead to chromosome instability and accumulation of mutation → defective checkpoints, cancer.

5.4.3 Topoisomerases

Programmed ssDNA and dsDNA breaks occur during transcription. As we have mentioned, positive and negative torsional stress generate forces opposing the direction of pol II. Topoisomerase cleavage complexes (TOPcc) assemble at sites of topological stress. They are tightly regulated to minimize deleterious cleavage complexes - their activity is impeded by nucleosomes. They are recruited to chromatin via interaction with chromatin remodelling complexes (SWI/SNF), histone chaperones (FACT) and helicase enzymes (WRN).

TOP1 triggers SSBs or nicks, TOP2 induces DSBs. Both perform breakage in a controlled manner and once torsion is released they can exert ligation activity. During transcription TOP1 and TOP2 enzymes relieve positive supercoils while TOP1 and TOP3 counteract negative supercoils.

5.4.3.1 A topoisomerase IIb-mediated dsDNA break required for Regulated Transcription

Biotin-dUTP labeling by terminal deoxy .. → only if a break is present. Amplification of the promoter region and not of the ORF, signaling the presence of a break in the promoter leading to the recruitment of PARP. However the break is transient, after 10 minutes it disappears.

DSBs are induced transiently on the pS2 promoter upon estrogen treatment. Transcriptional activation associates with transient and local formation of DNA double strand breaks. TopoII β -mediated DSBs at the pS2 promoter is required for pS2 transcription. If we block topoisomerases, machinery for transcription is not recruited. The presence of DNAPK persists for a while after the resolution of the break, this does only mean that the signal is spreading.

TopoIIb/PARP-1 complex in nuclear receptor-mediated gene regulation TopoII mediated DSB and in PARP-1 activity serves as mechanism for gene transcription upon ligand or signal- dependent




Figure 5.9: Screen Shot 2022-11-30 at 10-03-17.png

stimulation. PARP1 activity promotes removal of histone H1 from the ERE-containing nucleosome supporting transcription initiation.

5.4.3.2 BRCA1

Sometimes, pathological topoisomerase 2 sites are observed. OP2 is required for ER-mediated transcription. Occasional estrogen-induced pathological TOP2 occur with DSBs covalently associated with the enzyme. BRCA1 participates in resolving these structures promoting genome integrity. In the absence of BRCA1 estrogen exerts a genotoxic effect with accumulation of DSBs during cell divisions.

The roles of BRCA1 in the maintenance of genome integrity and regulation of transcription may be the key of its tissue specific tumor suppressor function. BRCA1 has an ubiquitinylase domain (RING) and a huge number of interacting proteins. BRCA1 drives a transcriptional program supporting differentiation of luminal progenitors to mature luminal cells. BRCA1 interaction inhibits ER α activity directly and by promoting mono-ubiquitination of ER α . BRCA1 mutant progenitors are aberrantly proliferative and defective in differentiation giving rise to tumors of luminal origin. Cells with LOH in BRCA1 usually show basal-like tumor activity.

5.4.3.3 Stark et al.

24h estrogen treatment activates DNA damage response pathways and associates with DSBs in MCF7 cells. **Comet assay:** cells are lysate, nuclei are inserted in an agarose pad and placed under an electrophoretic chamber (no fragmentation): if there are ds breaks it will move a little bit, we will observe a “comet” signal. In 24 hours cells can cycle and perhaps this is not the same break as topoisomerase II. Long term estrogen treatment results in greater DDR activation than short term treatments.

DNA damage induced by long term estrogen treatment is replication dependent, the more the cell proliferate, the more the DNA damage response is activated. If a Cdc7 inhibitor, DNA damage response activation is impacted. Flavopiridol (inhibits Cdk9) results in Pol II elongation impairment, but does not affect replication.

Estrogen induces R-loops formation at ER responsive genes. The induction of R loop was depending on ER target genes. Gene responsive to estrogen are enriched in genomic rearrangements in breast tumors. Somatic mutation data from whole genome seq of 560 breast tumors determining whether the mutation sites are enriched in estrogen responsive loci.

5.4. TRANSCRIPTION AND GENOME INSTABILITY II

Estrogen induced R-loops colocalize with DNA damage markers on chromatin. Proximity ligation assays suggest that estrogen induced R-loops occur on chromatin marked by DNA damage.

RNaseH expression reduces estrogen induced DNA damage. RNaseH expression reduces estrogen induced DSBs. R-loops may be involved in DNA damage induction DSBs formation in breast cancer cells upon estrogen treatment.

Summary

- Estrogen treatment induces replication and transcription dependent DNA damage
- DNA damage and DSBs induced by estrogen stimulation are linked to R-loop formation at ER responsive genes
- Breast cancer rearrangements are enriched at estrogen responsive loci where R-loops are detected upon estrogen treatment
- Many DSBs that accumulate upon estrogen treatment are R-loops dependent
- Estrogen stimulation leads to genome instability through R-loops formation and in a DNA replication dependent manner
- Also highlights an «alternative» mechanism by which a transcriptional program plays a role in genome stability in cancer